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Abstract
Amino-acid coevolution can be referred to mutational compensatory patterns preserving the
function of a protein. Viral envelope glycoproteins, which mediate entry of enveloped viruses
into their host cells, are shaped by coevolution signals that confer to viruses the plasticity to
evade neutralizing antibodies without altering viral entry mechanisms. The functions and
structures of the two envelope glycoproteins of the Hepatitis C Virus (HCV), E1 and E2, are
poorly described. Especially, how these two proteins mediate the HCV fusion process
between the viral and the cell membrane remains elusive. Here, as a proof of concept, we
aimed to take advantage of an original coevolution method recently developed to shed light
on the HCV fusion mechanism. When first applied to the well-characterized Dengue Virus
(DENV) envelope glycoproteins, coevolution analysis was able to predict important struc-
tural features and rearrangements of these viral protein complexes. When applied to HCV
E1E2, computational coevolution analysis predicted that E1 and E2 refold interdependently
during fusion through rearrangements of the E2 Back Layer (BL). Consistently, a soluble
BL-derived polypeptide inhibited HCV infection of hepatoma cell lines, primary human hepa-
tocytes and humanized liver mice. We showed that this polypeptide specifically inhibited
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HCV fusogenic rearrangements, hence supporting the critical role of this domain during
HCV fusion. By combining coevolution analysis and in vitro assays, we also uncovered func-
tionally-significant coevolving signals between E1 and E2 BL/Stem regions that govern HCV
fusion, demonstrating the accuracy of our coevolution predictions. Altogether, our work
shed light on important structural features of the HCV fusion mechanism and contributes to
advance our functional understanding of this process. This study also provides an important
proof of concept that coevolution can be employed to explore viral protein mediated-pro-
cesses, and can guide the development of innovative translational strategies against chal-
lenging human-tropic viruses.
Author summary
Several virus-mediated molecular processes remain poorly described, which dampen the
development of potent anti-viral therapies. Hence, new experimental strategies need to be
undertaken to improve and accelerate our understanding of these processes. Here, as a
proof of concept, we employ amino-acid coevolution as a tool to gain insights into the
structural rearrangements of Hepatitis C Virus (HCV) envelope glycoproteins E1 and E2
during virus fusion with the cell membrane, and provide a basis for the inhibition of this
process. Our coevolution analysis predicted that a specific domain of E2, the Back Layer
(BL) is involved into significant conformational changes with E1 during the fusion of the
HCV membrane with the cellular membrane. Consistently, a recombinant, soluble form
of the BL was able to inhibit E1E2 fusogenic rearrangements and HCV infection. More-
over, predicted coevolution networks involving E1 and BL residues, as well as E1 and BL-
adjacent residues, were found to modulate virus fusion. Our data shows that coevolution
analysis is a powerful and underused approach that can provide significant insights into
the functions and structural rearrangements of viral proteins. Importantly, this approach
can also provide structural and molecular basis for the design of effective anti-viral drugs,
and opens new perspectives to rapidly identify effective antiviral strategies against emerg-
ing and re-emerging viral pathogens.
Introduction
Flaviviridae such as Hepatitis C Virus (HCV), Dengue Virus (DENV), Zika Virus (ZIKV) or
West Nile Virus (WNV) are cause of several acute and chronic diseases worldwide. The con-
tinuous investigation of the molecular processes by which these RNA viruses infect and repli-
cate into their host is critical to develop innovative anti-viral strategies and anticipate viral
resistance to pre-existing drugs.
The high potency of viral genomes to mutate is often considered as a major limitation for
the development of effective anti-viral strategies. Nevertheless, the high-mutation rate of RNA
viruses represents a unique opportunity to decrypt viral protein functions and structures.
Highly-evolving viral genomes are shaped by important evolutionary constraints to maintain
genetic structure and proper protein folding. Amino-acid coevolution, which refers to muta-
tions of different residues at a similar time frame, mirrors such constraints. Hence, the identifi-
cation and characterization of coevolution signals imprinted within viral protein sequences
can provide unique insights into viral protein functions and conformational changes, and ulti-
mately guide the design of original anti-viral strategies.
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Virus entry is a conserved, critical step during the viral life cycle and represents a valuable
target for the development of antivirals and vaccines. The entry process of HCV is orchestrated
by two envelope glycoproteins, E1 and E2, which are incorporated onto the virion surface.
During entry, E1E2 mediate viral particle attachment to cell surface receptors and induce the
merging (called fusion) of endosomal and virus membranes at acidic pH, thus leading to
release of viral RNA into the cytosol [1]. Flaviviruses such as DENV, ZIKV or WNV harbor
two envelope glycoproteins: E and PrM. E is a class-II fusion protein composed of three dis-
tinct domains (domain I, II and III; or DI, DII and DIII respectively) and carries both binding
and membrane fusion properties [2]. Crystal structure of E at different pH allowed to draw a
fusion model during which initial E dimers change conformation and fold back as trimer
structures to induce membrane merging [3]. In contrast, how HCV E1 and E2 mediate mem-
brane fusion remains poorly defined. Our understanding of the HCV fusion process is strongly
dampened by the absence of a well-defined pre- and post-fusion full-length E1E2 crystal struc-
ture. Few studies have attempted to computationally model pre-fusion E1E2 complex [4,5] but
their impact remain limited as they have to rely on partial structural and functional informa-
tion that are often collected in a non-heterodimer context.
The structure of a large region of the E2 ectodomain (E2 core) [6,7] exhibits a globular,
non-extended fold divided into two distinct sheets: a front sheet composed of a front layer and
a central Ig-fold domain, and a back sheet (or back layer, BL). Although the central Ig-fold
domain represents a common structure among class-II fusion proteins, the BL harbors an
original structure, thus undermining the possibility that HCV E2 is a classical fusion protein.
It has been suggested through the resolution of the bovine viral diarrhea pestivirus (BVDV-1)
E2 glycoprotein structure that HCV E1 may represent the HCV fusion protein [8–10]. Several
studies have identified a hydrophobic region in E1 (CSALYVGDLC) that could represent the
putative HCV fusion peptide [11–16]. Another study also suggested that E1 proteins form tri-
meric structure at the virus surface [17]. However, the recent crystal structure of the N-termi-
nal domain of HCV E1 ectodomain does not harbor the expected truncated class-II fusion
protein fold [18], suggesting that HCV fusion might be a unique process.
Mutagenesis studies have shown that both E1 and E2 domains, as well as E1-E2 dialogs, are
involved in the HCV fusion process [13,14,19–21]. Thus, rather than being mediated by a sin-
gle glycoprotein, HCV fusion appears to be mediated by complex intra- and inter-molecular
E1-E2 dialogs that shape structural and conformational rearrangements of the heterodimer
complex. Consequently, the characterization of interplays between E1 and E2 is critical to deci-
pher the HCV fusion mechanism.
Here, using HCV fusion as a model of study, we aimed to provide a proof of concept that
amino-acid coevolution and protein evolutionary constraints can shed light on viral protein func-
tions and rearrangements. We hypothesized that detection of E1-E2 coevolution patterns can
uncover their functional interplays as well as critical features of the HCV fusion mechanism.
We recently developed an original computational method, Blocks In Sequences (BIS), that
can robustly detect coevolution signals within conserved cellular and viral proteins using a
limited number of protein sequences [22–24]. Taking advantage of this methodology, we aim
at establishing a map of E1-E2 coevolution patterns and test whether coevolution analysis can
be employed to gain mechanistic insight into poorly characterized viral processes such as
HCV fusion. BIS was able to accurately predict features of DENV glycoproteins structural
organization onto viral particle, as well as E fusogenic conformational changes. When applied
to HCV E1E2, BIS suggested that HCV E2 BL is a critical modulator of HCV fusion. Consis-
tently, a soluble form of the E2 BL was able to inhibit HCV fusion. Moreover, coevolution sig-
nals between E1 and E2 BL/Stem predicted by BIS were found to regulate virus fusion in vitro.
Beyond providing novel insights into the HCV fusion mechanism, our work also demonstrates
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that coevolution analysis can shed light on viral-mediated processes and can open avenues for
the accelerated design of innovative anti-viral compounds against challenging human tropic-
viruses.
Results
A computational coevolution-based method recapitulates DENV
glycoproteins structural organization
We have previously reported that BIS, a combinatorial-based coevolution analysis method (S1
Fig), can accurately detect coevolution signals within a wide range of well-characterized cellu-
lar and viral proteins [22–24]. As BIS has not been previously tested for its ability to predict
viral envelope glycoproteins structural organization and rearrangements, we first performed a
coevolution analysis of the well-characterized DENV envelope glycoproteins, E and PrM [2,3].
During virus maturation, M protein (a mainly transmembranous protein) is associated to Pr, a
peptide that protect the E fusion peptide and is cleaved prior viral budding [25]. Briefly, the
PrM-E complex protrude as trimer at the surface of immature viral particles in the endoplas-
mic reticulum, a neutral pH compartment. Immature particle then navigates toward the trans-
Golgi network, a more acidic compartment, where PrM-E complex form dimeric structures
that lie down onto the surface of the particles. Pr, which initially concealed E fusion peptide, is
then cleaved by the Furin. This cleavage achieves the maturation of viral particles that are then
released into the extracellular compartment. As M is mostly a transmembrane protein with
only very partial structural information available, we aimed to determine whether BIS can
recapitulate the diversity of E-Pr structural organization at the surface of immature viral parti-
cles. BIS analysis of 17 DENV PrM-E serotype 2 sequences led to the identification of 14
groups of coevolving residues (possibly organized in blocks of consecutive amino-acids), fur-
ther referred as clusters (S1 Table). Among those, three clusters (cluster 2, 7 and 9) displayed a
strong statistical significance (with associated p values of 8e-5, 8e-5 and 7e-3 respectively) and
involved coevolving blocks between E and Pr. When E is assembled as dimer at low pH condi-
tion, cluster 2 coevolving block positions supported the close proximity of E DIII and Pr (Fig
1A and 1B-left). Similarly, cluster 7 also recapitulated the close proximity between Pr and E
domain DII on a trimeric E-Pr structure that form at neutral pH in the endoplasmic reticulum
(Fig 1A and 1B-center). On a trimeric Pr-E structure (one dimer + one monomer of PrM-E)
found at low pH when particles mature in the trans-Golgi, cluster 9 also supported a close
proximity between Pr and E DII, but also between E dimers (Fig 1A and 1B-right). Two other
clusters (cluster 3 and 8) of strong statistical significance (with respective p values of 1.34e-5
and 4.11e-5) were identified by BIS but did not involve coevolving residues located within E
protein (S1 Table). Although cluster 8 was composed of two coevolving blocks located within
M protein only, clusters 3 involved coevolving residues located within both M and Pr. As clus-
ter 3, cluster 2 and 9 also supported the existence of interactions between Pr and M (Fig 1A
and 1B). As M and Pr are the two cleavage products of a single PrM protein, these three clus-
ters hence represent additional evidence of BIS ability to recapitulate biologically significant
protein interactions. Taken together, our results demonstrate that BIS has the ability to accu-
rately predict the tridimensional assembly of two viral proteins within different conforma-
tional states.
BIS can predict DENV E fusogenic conformational changes
As DENV E has been demonstrated to mediate DENV viral fusion, we then aimed to study the
intra-protein coevolution signals within DENV E only (Fig 2A; see new E numbering by BIS
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in comparison to Fig 1A), and determined whether coevolution signals can also predict E fuso-
genic rearrangements. Using 17 different DENV E serotype 2 sequences, BIS identified 12 clus-
ters (S2 Table). Among them, nine clusters (clusters 2–8 and 11,12) displayed associated p-
values ranging between 7e-3 to 2e-7 and two clusters (clusters 9 and 10) exhibited associated
p-values of 0.058 (S2 Table). Cluster 1 and 2 were either conserved (p-value = 1) or too large
respectively to be considered. Several clusters (3,4,6 and 7) displayed small blocks located
within a single region of E both in the linear protein sequence and on the tridimensional struc-
ture, suggesting that coevolution signals might contribute to the structural organization of sec-
ondary protein sub-domains (such as internal loops) (S2 Fig). DENV E DI and DII are
composed of two or three sub-domains that are distant on the linear protein sequence but
form single structured domains in the protein tertiary structure. Cluster 8 blocks were mostly
located within the two sub-domains of DII and were consistent with the tridimensional orga-
nization of this protein domain (Fig 2B). Cluster 8 blocks located within the second sub-
domain of DII (DII-2) of each E monomer were in close contact on the dimeric E structure
(especially at the level of the DII α-helix), hence suggesting that coevolution signals can predict
point of contacts between E monomers once organized as dimer (Fig 2B). Despite lower
Fig 1. BIS analysis of dengue E-Pr coevolving residues. (A) Tridimensional representation of DENV Pr (Black, PDB 3C6R) and E
(multi-color, PDB 1K4R). A linear representation of the PrM-E polyprotein is depicted below the protein structures. Starting and
ending residue positions of each protein (Pr, M and E) and E domain are indicated. E domains are annotated by distinct colors: DI,
domain I (red); DII, domain II (yellow); DIII, domain III (blue); Tmd, transmembrane (black). (B) Organization and positions of the
PrM-E cluster 2 (orange), 7 (blue) and 9 (pink) on tridimensional representations of the DENV E and Pr proteins. Cluster 2 and 9 are
depicted on a dimeric or trimeric E-Pr structure respectively at low pH condition (PDB 3C6R). Cluster 7 is depicted on a trimeric
E-Pr structure at neutral pH condition (PDB 3XIY). Linear representation of the two proteins are also depicted on the top of each
structure and cluster block location are indicated (precise cluster positions are reported in S1 Table). The close proximity between
DENV E and Pr cluster 2 blocks is enlarged.
https://doi.org/10.1371/journal.ppat.1006908.g001
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statistical significance (p<0.06), cluster 9 and 10 coevolving blocks also supported E structural
organization as these blocks were distant on the linear structure but close on the E dimer struc-
ture (S2 Fig). Finally, three clusters (5, 11 and 12) displayed coevolving blocks that were both
distant on the linear and tridimensional E structure. During fusion, E DIII folds-over toward
DII, and DII becomes at close proximity with the E transmembrane domain [3] (Fig 2C).
Cluster 5 and 11 coevolving blocks organization were consistent with these structural rear-
rangements (Fig 2C), suggesting that BIS can recapitulate viral glycoprotein fusogenic confor-
mational changes.
HCV E1 and E2 are strong coevolving partners that likely refold
interdependently during fusion
Following validation of BIS ability to model viral envelope glycoprotein structural rearrange-
ments, we then applied the BIS methodology to HCV E1E2. We analyzed independently using
BIS ten groups of E1E2 sequences from different genotypes (gt) or sub-types (1a, 1b, 1 = 1a
+1b, 2a, 2b, 2 = 2a+2b, 3, 4a, 5a and 6a) (S3 Table). Interestingly, most of the identified clusters
involved residues in both E1 and in E2 suggesting the existence of conserved tight dialogs
Fig 2. BIS analysis of dengue E coevolving networks during pre- and post-fusion steps. (A) Linear representation of Dengue
E protein. Starting and ending residue positions of each E domain are indicated. E domains are annotated by distinct colors: DI,
domain I (red); DII, domain II (yellow); DIII, domain III (blue); Tmd, transmembrane (black). (B) Organization and positions
of the DENV E cluster 8 blocks (dark blue) on a mature E dimeric structure (PDB 1K4R). A linear representation of E is depicted
and cluster block locations are indicated (precise cluster positions are reported in S2 Table). Cluster 8 coevolving residues
located in areas where the two E monomers are in close contact are enlarged (green square). Structural proximity of two-
coevolving cluster 8 internal loops located into two distinct Domain II (DII) sub-domains on the linear structure is also
highlighted (red square). (C) Positions of E cluster 5 (red) and 10 (green) blocks on a mature tridimensional E monomer at a
pre-fusion state (left, PDB 1K4R) and post-fusion state (right, PDB 1OK8). Stem and transmembrane domains are represented
by a grey dotted line. A linear representation of E and cluster block locations are indicated for each cluster (precise cluster
positions are reported in S2 Table). At the top of the panel, a schematic represents the current experimentally-validated fusion
model of DENV, and how DENV E rearranges during this process. DENV E domains are colored into distinct colors (red,
domain I; yellow, domain II; blue, domain III) as in Fig 1A.
https://doi.org/10.1371/journal.ppat.1006908.g002
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between E1 and E2 proteins (Fig 3A). Only a few number of statistically significant clusters
were found among genotype 4a to 6a sequences, due to the low number of sequences available
and to their very low genetic divergence.
Unlike Dengue E and PrM, the full panel of HCV E2 conformations still remain unknown
and E2core only represent a single of these possible conformations, in a given biochemical
context. When BIS coevolution analysis is applied to protein(s) for which only a fraction of its/
Fig 3. BIS analysis of HCV E1E2 coevolving residues. (A) Number of intra-E1 (red), intra-E2 (blue) and inter-E1E2 (purple) clusters
detected by BIS following analysis of E1E2 sequences belonging to genotype 1 through 6. (B) Linear representation of HCV E1E2
glycoproteins and tridimensional representation of E2core structure (PDB 4MWF). E2 domains and their residue positions are indicated.
E2core layers and domains are highlighted by distinct colors (Green, BL; Red, central β-sandwich; Blue, front layer; Dark blue, CD81 BinL/
CD81 binding loop; Light grey, central β-sandwich–back layer linker; Black dotted line, VR2/Variable Region 2; Grey dotted line, Stem;
Black rectangle, Tmd/Transmembrane). HVR1, Hyper Variable Region 1. Rotation angles of the E2core structure are indicated. Viewing
angle of E2core is indicated by a black cross harboring 4 color points at each extremity. (C-E) HCV E1E2 gt1a (C-D) and gt2 (2a+2b, (E))
fusion clusters are plotted on a vertical linear representation of E1 combined to the tridimensional view of E2core (PDB 4MWF). Each
cluster is composed of blocks harboring a similar color, according to S3 Fig (gt1a) or S6 Fig (gt2). Panel C shows E1E2 dialogs mediated
by gt1a fusion cluster 5 and 7 and panel D underlines E1E2 dialogs mediated by gt1a fusion cluster 8, 10 and 12. Panel E shows E1E2
dialogs mediated by gt2 fusion cluster 10 and 13. The Stem region (Stem) is represented by a dotted line following the C-terminal part of
the BL. The transmembrane domain (Tmd) is represented as a rectangle following the Stem region. Bold lines link E1 and E2 cluster
blocks that coevolved. For each cluster, block positions in E1 (at the left of the linear structure) and E2 (below boxes whose color match the
color of the corresponding cluster) are indicated. Rotation angles of the E2core structure are indicated and the viewing angle of E2core is
indicated by a black cross (as in Fig 3B).
https://doi.org/10.1371/journal.ppat.1006908.g003
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their conformations have been characterized (which is the case for HCV E1 and E2), BIS
coevolution clusters can thus only suggest, but not contradict a given conformational hypothe-
sis, this unless the full panel of a protein conformations is known. Consequently, in vitro and/
or in vivo experiments are then critical to ascertain the functional significance of a given con-
formational hypothesis.
Given this particular experimental context and in order to identify putative E1E2 rearrange-
ments during HCV fusion, we thus adopted the following approach. First, we aimed to assign
to each E1E2 cluster a given function by mapping clusters blocks with residues previously
identified in the literature to impact E1E2 folding/heterodimerization, binding or fusion. Sec-
ond, we sought to identify among BIS clusters classified as “fusion clusters” a putative protein
rearrangement supported by several fusion clusters across multiple genotypes, prior experi-
mental challenge through in vitro experiments.
We first focused our efforts on analyzing gt1a clusters. Detailed analysis of these clusters
(S4 Table; S3 Fig; note that BIS numbered E1 and E2 residues by considering the first amino
acid of E1 as residue #1) showed E1 as coevolving systematically with all the E2 domains. Plot-
ting the gt1a coevolving blocks onto reference sequences (S4 Fig) revealed a strong correlation
between blocks and residues previously identified in the literature to be important for hetero-
dimer folding or viral binding site conformation (grouped both under the term “structural”)
or fusion. This correlation allowed us to propose functions (structural, fusion, or multifunc-
tional clusters) for most gt1a clusters (S5 and S6 Tables). When plotted on the E2core struc-
ture (Fig 3B), most fusion clusters involved blocks located within the E2 BL (Fig 3C and 3D)
in contrast to structural or multifunctional clusters for which blocks were broadly distributed
across E2 (S5 Fig). Interestingly, some of the fusion clusters involved distant blocks in both E1
and E2 (clusters 5,7,10; Fig 3C and 3D), highlighting that E1 terminal regions and the E2 BL
could be in close proximity during fusogenic rearrangements. In addition, BIS also suggested
an association between fusogenic rearrangements and a potential packing of E2 domains (clus-
ters 8,10; Fig 3C and 3D). Thus, BIS proposed that interdependent rearrangements of E1 and
BL could represent a hallmark of E1E2 fusogenic conformational changes.
Analysis of clusters from another HCV genotype (gt2) provided similar findings as fusion
clusters also involved the BL (cluster 10,13) as well as distant blocks on E1 (cluster 6,10) and
E2 (cluster 10,16) (Fig 3E; S6–S8 Figs; S7–S9 Tables). Statistically significant coevolution net-
works between E1 and BL were also found among genotype 3 sequences (S9 Fig). Similar net-
works were also found among sequences of genotype 4 to 6, but displayed poor statistical
significance for the reason described above. Genotype 3 to 6a cluster positions are available
through the webpages indicated in the data availability statement.
HCV E1 and E2 transmembrane were previously shown to be critical for E1E2 heterodi-
merization and correct E1E2 functions [26–28]. Consistently, BIS was also able to identify sev-
eral coevolution clusters between the transmembrane of E1 and E2 using sequences of
genotype 1 and 2 (S10 Table), hence strengthening the functional significance of BIS analysis.
In parallel, BIS also revealed several gt1a and gt2 structural and multifunctional clusters as
supportive of the E2core central scaffold structure (S5 and S8 Figs), reinforcing BIS as a rele-
vant method to model viral protein conformations. The detailed analysis of all the clusters of
gt1a and 2, regardless of their attributed function, can be found in S1 and S2 Texts
respectively.
Altogether, BIS coevolution analysis of E1E2 sequences suggested that E2 may adopt a pre-
fusion structure distinct from E2core as well as yet unreported molecular rearrangements that
could occur during fusion. We hence hypothesized that a movement of the BL (green; Fig 4A),
through dialogs with E1, could mediate the evolution from a potential stretched E2 pre-fusion
structure toward a domain-packed E2 post-fusion structure (Fig 4B).
A coevolution approach to decrypt the HCV fusion mechanism
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A soluble form of the back layer inhibits HCV infection
To challenge the potential role of the BL in E1E2 rearrangements, we generated a soluble 9kDa
6His-tagged BL domain (71 aa; named BLd-H77; Fig 4C; S10A Fig) from the H77 gt1a strain,
detectable through Coomassie blue staining and Western immunoblotting (Fig 4D and 4E).
Non-reducing SDS-Page electrophoresis and Dynamic Light Scattering (DLS) analysis (S10B
and S10C Fig) confirmed the homogeneity of the peptide in solution and suggested that BLd-
H77 fold as a monomer. The far UV circular dichroism (CD) spectrum of BLd-H77 eluted
from size exclusion chromatography displays the molar ellipticity per residue expected for a
protein folded mainly in α-helix (S10D Fig). We next assessed its effect on HCV infection.
Interestingly, BLd-H77 was able to inhibit, in a dose-dependent manner, infection of Huh7.5
cells by replicative hepatoma cell line-derived HCV particles (HCVcc) harboring envelope gly-
coproteins of gt1a (H77/JFH-1) but also gt2a (JC1) (Fig 4F; S11A Fig). Although BLd-H77
was able to slightly inhibit HCVcc infection when pre-incubated with cells prior infection, it
showed a strong potency to inhibit infection when present during the first four hours of infec-
tion (Fig 4G) thus suggesting that BLd-H77 might likely act on early steps of the virus life
cycle. Consistently, BLd-H77 was able to efficiently inhibit infection of Huh7.5 by non-replica-
tive retroviral pseudoparticles harboring HCV E1E2 (HCVpp) from different genotypes (Fig
4H and 4I; S11B Fig). This inhibition was specific as BLd-H77 was not able to inhibit infection
by pseudoparticles harboring VSVG envelope (VSVGpp). Time-course experiments using
BLd-H77 (Fig 4I) as well as two additional entry inhibitors, Bafilomycin A1 that acts on cell
endosome acidification [29]) and an anti-E2 neutralizing antibody (that binds to E1E2 com-
plexes [30]), demonstrated that BLd-H77 is an entry inhibitor that likely acts on viral particles
(S11C Fig) but not on cells. No effect of BLd-H77 on HCV cell entry receptors expression
could be observed (S11D Fig). Moreover, BLd-H77 was also able to inhibit cell-to-cell trans-
mission (S11E Fig) in addition to cell-free infection (Fig 4F and 4G). Altogether, these results
highlighted that BLd-H77 likely inhibits a conserved mechanism during HCV entry without
affecting cell susceptibility for infection. Importantly, BLd-H77 was able to inhibit HCVcc and
primary human hepatocytes-derived HCVcc virus (or HCVpc) infection of primary human
hepatocytes (PHH) and Huh7.5 respectively (Fig 4J and 4K; S11F Fig). Finally, we assessed
the ability of BLd-H77 to inhibit infection in vivo. BLd-H77 showed a potency to inhibit
HCVcc JC1 infection over time in humanized liver mice treated with 150 μg of BLd-H77
under a prophylactic protocol (Fig 4L). Despite their uneven infectivity [31], our results also
suggested that BLd-H77 is able to inhibit patient-derived HCV particles infection in human-
ized mice p = 0.02 for all quantifiable values equal and above the detection limit) as well as in
PHH (S11G and S11H Fig). BLd-H77 had no impact on human hepatocyte viability in mice
as assessed by serum albumin concentration over the course of infection (S11I Fig). Alto-
gether, our results indicate that BLd-H77 is able to inhibit entry of different types of HCV par-
ticles in vitro and in vivo and thus target a strongly conserved virus entry mechanism.
BLd-H77 binds viral particles via E2
We then sought to elucidate how BLd-H77 blocks HCV entry. By pre-incubating viral particles
with BLd-H77 and diluting the mix prior to infection to reach a BLd-H77 concentration below
its efficient neutralizing activity (determined in Fig 4F and 4H), we showed that BLd-H77
could irreversibly neutralize HCV particles regardless of mix dilution, hence suggesting that
BLd-H77 can bind native viral particles prior viral entry (Fig 5A). To assess the presence of an
interaction between HCV particles and the BLd-H77, we constructed a transmembrane form
of BLd-H77 (called BLd-tm) (Fig 5B). Following lentiviral transduction, BLd-tm expression
was detectable at Huh7.5-BLd-tm surface (S12A Fig), and did not impact HCV receptor
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Fig 4. An E2 BLd-derived peptide inhibits HCV infection. (A) Putative BL movements that can modulate E2
rearrangements within E1E2 heterodimers. Rotation angles of the E2core structure are indicated (Reference: Fig 3B) and
illustrated by a black cross harboring 4 color extremities. (B) Schematic representation of the E2 core structure and of
the two hypothetical E2 conformational states prior (stretched) and following (packed) virus fusion when E1E2 are
associated as heterodimer (color code and angle of E2 structures refer to Fig 3B). (C) Schematic representation of the
expression construct encoding for the BLd-H77 peptide derived from the gt1a H77 E2 glycoprotein. SP, signal peptide;
6H, 6His-tag. (D) Detection of BLd-H77 in non-reducing condition following SDS-Page electrophoresis and coomassie
blue staining. Molecular weight of the reference ladder are indicated on the left (kDa). (E) Detection of BLd-H77 peptide
by Western Blot using a 6His-tag antibody. A 6His-tagged soluble E2 was used as a positive control. (F) Dose-dependent
inhibition of HCVcc infection. HCVcc H77/JFH-1 or JC1 were pre-incubated with different doses of BLd-H77 (μg/ml)
and used to infect Huh7.5 cells. Percentages of primary infection were calculated according to the viral titers of HCVcc
particles incubated without BLd-H77 (mean ± SD; n = 3). (G) Kinetic of action of BLd-H77 on HCVcc infection. Huh7.5
cells were incubated 1h with BLd-H77 prior infection (35μg/ml) of HCVcc H77/JFH-1 (2), during the 4h infection (3) or
following infection (secondary infection; 4). As control, cells were incubated at each step with equivalent volume of PBS
(1). Percentages of primary infection were calculated according to viral titers of control conditions (mean ± SD; n = 3).
Statistical significances (p<0.05, p<0.01, p<0.001) were determined for each experimental condition versus
control condition (100%). (H) Dose-dependent inhibition of HCVpp harboring H77 envelope (HCVpp-H77) or control
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expression (S12B Fig). BLd-tm expression at Huh7.5 surface, but not expression of a similar
construct encoding for an anchored HIV-1 fusion inhibitor (namely C46), inhibited HCVcc
propagation both in a cell-free and cell-to-cell transmission manner (Fig 5C and 5D; S12C
Fig). HCVpp entry, but not VSVpp entry, (Fig 5E) was inhibited following infection of
Huh7.5-BLd-tm, hence highlighting that BLd-H77 specifically inhibits HCV entry likely
through binding of E1E2 glycoproteins. Consistently, more HCVpp were detected at Huh7.5-
BLd-tm cell surface 4h post infection in comparison to Huh7.5 (S12D Fig), suggesting a poten-
tial containment of HCV particles by BLd-tm at the cell surface. The ability of recombinant
soluble E2 (sE2) to bind more efficiently Huh7.5-BLd-tm cells than Huh7.5 cells in a dose
dependent manner (Fig 5F) further suggested that virus entry is inhibited through an interac-
tion between E2 and BLd-tm. In order to explore more precisely a putative interaction between
E2 and BLd-H77, we designed an ELISA assay to quantify the ability of sE2 to be captured by
coated BLd-H77. Our result showed a significant ability of sE2 to bind coated-BLd-H77 and
coated-anti-E2 antibody AR3B [32] but not a coated-mouse IgG isotype (Fig 5G; S12E Fig).
Altogether, these results strong suggest that BLd-H77 inhibit HCV entry by binding to E2
glycoprotein.
BLd-H77 inhibits virus fusion
Next, we explored which step of HCV entry is inhibited by BLd-H77. BLd-H77 had no signifi-
cant effect on attachment of HCVcc (HCVcc JC1, Fig 5H), HCVpp-H77 particles or soluble
E2 (S13A Fig) on Huh7.5 cells. Using a highly specific and previously established HCVpp
binding assay [21], we confirmed that BLd-H77 does not abrogate HCVpp binding to either
human CD81 or SR-BI when used at a highly neutralizing concentration (S13B–S13D Fig).
Moreover, BLd-H77 neutralizing activity was not competing with the activity of a neutralizing
anti-E2 antibody known to inhibit viral particle binding [30], and their use in combination
showed a synergistic neutralization effect (S13E Fig). Consistently, BLd-H77 could bind viral
particles following their binding at the cell surface, and was shown to have its more potent
neutralizing activity during post-binding steps (Fig 5I). Using a cell-cell fusion assay, we
showed that BLd-H77 could strongly inhibit cell-to-cell fusion in comparison to control enve-
lope glycoproteins (Fig 5J; S14A Fig). Importantly, cell-to-cell fusion was only inhibited when
pseudoparticles harboring VSV-G (VSVGpp) envelope glycoprotein. Pseudoparticles were pre-incubated with different
doses of BLd-H77 (μg/ml) or with PBS and used to infect Huh7.5 cells. Percentage of GFP positive cells was determined
and expressed as percentages of infection, according to the viral titers of HCVpp incubated with PBS (mean ± SD; n = 3).
(I) Kinetic of action of BLd-H77 on HCVpp infection. Huh7.5 cells were incubated 1h with BLd-H77 prior HCVpp H77
infection (50μg/ml) (2), during the 4h infection (3) or following infection (4). As control, cells were incubated at each
step with equivalent volume of PBS (1). Percentages of infection according to viral titers of control conditions are
reported (mean ± SD; n = 3). Statistical significances (p<0.01, ns non-significant) were determined for each
experimental condition versus control condition (100%). (J) Dose-dependent inhibition of HCVcc JC1 virus infection of
primary human hepatocytes (PHH). JC1 particles were pre-incubated with different doses of BLd-H77 (μg/ml) or with
PBS and then used to infect PHH. PHH cell culture media were harvested four days post-infection and used to infect
naïve Huh7.5 cells. Percentages of secondary infection are shown and calculated according to the viral titers of JC1 virus
pre-incubated with PBS (mean ± SD; n = 3). (K) Dose-dependent inhibition of JC1-derived HCVpc (HCV primary cell
culture-derived) of Huh7.5. HCVpc particles were pre-incubated with different doses of BLd-H77 (μg/ml) or with PBS
and used to infect naïve Huh7.5 cells. Percentages of primary infection using HCVpc particles are shown and calculated
according to the viral titers of JC1 virus pre-incubated with PBS (mean ± SD; n = 3). (L). Inhibition of HCV infection in
vivo in humanized liver mice. JC1 infectious titers (FFU/ml) were obtained from two independent mice cohorts treated
with 30μg (red, n = 3) or 150μg (blue, n = 2) of BLd-H77, or with PBS (black; cohort = 6) under a “prophylactic”
protocol. BLd-H77 or PBS was injected one day prior virus infection with JC1 HCVcc particles and subsequent
injections were performed at day 1, 7 and 14 post-infection. Sera were harvested 7 (Week 1), 14 (Week 2) and 21 days
(Week 3) post-infection. HCV viral titers were determined through infection of Huh7.5 cells with mouse sera and
quantification of FFU/ml. One non-engrafted liver mice and one non-infected mice were used as negative controls
(green, n = 2). N.D., non-detected.
https://doi.org/10.1371/journal.ppat.1006908.g004
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Fig 5. A transmembranous form of BLd-H77 inhibits HCV infection. (A) BLd acts onto viral particles. H77 HCVpp
or H77/JFH-1 HCVcc particles were pre-incubated with BLd-H77 (50μg/ml or 35μg/ml, respectively) or with PBS. Prior
to infection of Huh7.5 cells, HCV particles and BLd-H77 mixes were diluted (1/5; +) or not (-) with cell culture media
resulting in a BLd-H77 concentrations inhibiting infectivity by less than 20% (see Fig 4F and Fig 4H). Viral titers of
primary infection were determined 72h (HCVpp) or 4 days (HCVcc) post-infection and expressed as percentages of
infection according to PBS control experiments (mean ± SD; n = 3). Statistical significances (p<0.05, p<0.001) were
determined for each experimental condition versus control condition (100%). (B) Schematic representation of the BLd-
H77 transmembrane form (BLd-tm) and its possible mode of action. An IgG2 hinge region (Hinge) and the
transmembrane region of the CD34 molecule (MSD) were added to the C-terminal of BLd-H77. SP, signal peptide. (C) A
BLd-H77 transmembranous form inhibits HCVcc infection. H77/JFH-1 HCVcc were used to infect non-transduced
Huh7.5, Huh7.5-C46 (C46) and Huh7.5-BLd-tm (BLd-tm). Four days post-infection, FFU titers were determined for
each cell type and percentages of primary infection were normalized according to the viral titers determined following
Huh7.5 infection (mean ± SD; n = 3). Statistical significances (p<0.001, ns non-significant) were determined for each
experimental condition versus control condition (100%). (D). Propagation of HCVcc viral particles in Huh7.5-BLd-tm
cell cultures. Huh7.5 and Huh7.5 BLd-tm cells were infected with HCVcc H77/JFH-1 at a m.o.i. of 0.1. At day, 1, 3 and 5
post-infection, cell culture supernatants were harvested and used to infect naïve Huh7.5 cells. Viral titers of secondary
infection were determined by NS5A immunostaining four days post-infection (mean ± SD; n = 3). (E) BLd-tm inhibits
cell entry. Non-transduced Huh7.5 and Huh7.5-BLd-tm were infected with HCVpp H77 and VSVpp. 72h post infection,
amount of GFP positive cells were quantified. Percentage of infection of Huh7.5-BLd-tm is normalized for each type of
particle on the percentage of infection of non-transduced Huh7.5 (mean ± SD; n = 3). Statistical significances (p<0.01,
ns non-significant) were determined for each experimental condition versus control condition (100%). (F) Soluble E2
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cells were incubated with BLd-H77 before low pH exposure that activate membrane fusion
(S14B Fig), underlining BLd-H77 ability to specifically binds E1E2 pre-fusion conformations.
Finally, using a HCVpp fusion assay with liposomes, which are devoid of any receptors or cell
factors, the BLd-H77 inhibited fusion in a dose-dependent manner (Fig 5K, S14C Fig). Alto-
gether, these results suggest that BLd-H77 specifically blocks E1E2 fusogenic rearrangements
and the formation of post-fusion structures through binding to E2 protein, in accordance with
BIS predictions.
E1E2-BL dialog is critical for fusion
Beside highlighting potential E1E2 rearrangements during fusion, BIS can identify pairs of res-
idues that need to mutate in concert to guarantee structural compensations and proper viral
fitness. Indeed, we have previously demonstrated how HCV entry depends on strain-specific
dialogs between particular E1 and E2 domains [21]. Thus, we aimed at addressing whether BIS
is able to unveil specific dialogs between residues of E1 and the E2 BL that modulate HCV
fusion. The BIS predictions identified the multifunctional gt2 cluster 5 (S7–S9 Tables) as an
interesting candidate for supporting E1 and E2 dialogs, BL movements and transition from
E1E2 pre-fusion to post-fusion states. This cluster, similar to gt1a fusion cluster 5, linked two
central blocks in E1 (residues 104, 105, and 109) and one block in E2 BL (residues 427 to 436;
orange; Fig 6A). In order to challenge its potential role during fusion, we used cluster 5 blocks
to guide the rational design of E1E2 chimeric constructs. The E1 region containing two cluster
5 blocks (Fig 6B; Region 1) and E2 BL regions containing the other cluster 5 block (Fig 6B;
Region 2) or not (Fig 6B; Region 3, non-coevolving cluster 5 block as a control of specificity)
were swapped between two E1E2 heterodimers from different gt2 strains, one allowing effi-
cient HCVpp entry (J6) and another one mediating sub-optimal HCVpp entry (2b1) (S15A
binding to Huh7.5-BLd-tm cells. Different doses of soluble E2 were mixed with different concentrations of Huh7.5 and
Huh7.5-BLd-tm cells and E2 binding was quantified by flow cytometry. Results represent E2 ability to bind Huh7.5-BLd-
tm cells for each condition relatively to the basal E2 ability to bind Huh7.5 cells (determined as 0% binding) for the same
condition (mean ± SD; n = 3). p<0.05. (G) Interaction between BLd-H77 and sE2 detected by ELISA. Different
amounts of mouse IgG isotype, AR3B and BLd-H77 were coated overnight into 96-well plates. Coated peptides and
antibodies were then incubated with 10ng of soluble E2 (sE2) or not. After washing, soluble E2 was detected using the rat
anti-E2 antibody 3/11 and an anti-rat HRP antibody. After measurement of the optical density (O.D.) at 450nm, relative
E2 binding was determined by calculating the ratio of O.D. between condition with 10ng of sE2 and no sE2, for each
coating condition (mean ± SD; n = 3). p<0.01, p<0.001, p<0.0001, ns non-significant. (H) BLd-H77 does not
affect HCVcc binding. JC1 HCVcc particles were pre-incubated with BLd-H77 (35 μg/ml), Heparine (250 μg/ml) or PBS
and mixed with Huh7.5 cells for 2h at 4. After washing, amounts of cell-associated viral particles were determined by RT-
qPCR (mean ± SD; n = 3). Data are shown as percentage of binding, according to binding of HCVcc particles in control
condition (PBS). Statistical significances (p<0.05, ns non-significant) were determined for each experimental condition
versus control condition (100%). (I) BLd-H77 can inhibit HCV entry following particle binding. HCVpp particles
(HCVpp-H77) were incubated with Huh7.5 in presence of BLd-H77 (50μg/ml) or AR4A (25 μg/ml) during binding (1h
at 4˚C; 2), entry (4h at 37˚C following binding; 3), or following entry (72h at 37˚C following media change; 4). GFP levels
were quantified 72h post infection. Huh7.5 infected in a similar manner but non-treated with BLd-H77 or AR4A were
used as control (1). Percentages of infection were calculated based on viral titer obtained from control conditions.
(mean ± SD; n = 3). Statistical significances (p<0.001, ns non-significant) were determined for each experimental
condition versus control condition (100%). (J) Effect of BLd-H77 on cell-cell fusion. LTR-luciferase-transduced 293T
cells expressing HCV-H77 E1E2 or VSVG glycoproteins were co-cultivated with Tat-expressing Huh7.5 cells. Following
pre-incubation with PBS or with 50μg/ml of BLd-H77, co-cultured cells were exposed to an acid shock (pH5) or not
(pH7) and luciferase activities were determined 72h post-exposure. Percentage of fusion of HCV and VSVG
glycoproteins at pH5 between control (PBS) or BLd-H77 are indicated (mean ± SD; n = 3). Statistical significances
(p<0.01, p<0.001) were determined for each experimental condition versus control condition (100%). (K) Effect of
BLd-H77 on virus-liposome fusion assays. H77 HCVpp particles were pre-incubated with different dose of BLd-H77
(50μg/ml, green; 100 μg/ml, blue; 150 μg/ml, red) or not (PBS, black), and mixed with R18-labelled liposomes.
Dequenching of R18 was quantified following sample acidification (pH5). Data are represented as non-linear polynomial
fitted curves for each experimental condition and display the evolution of the fusion rate (%) over time. Curves are
representative of three independent experiments.
https://doi.org/10.1371/journal.ppat.1006908.g005
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and S15B Fig). All chimeras were similarly expressed and incorporated (S15C Fig). Although
J6 chimera carrying 2b1 cluster 5 regions (J6-1/2) displayed a poor entry efficiency, similar to
2b1 parental glycoproteins, a 2b1 chimera carrying J6 cluster 5 regions (2b1-1/2) exhibited
>10-fold improved entry ability (Fig 6C). In contrast, 2b1 chimera carrying J6 Region 1 and 3
(2b1-1/3; Fig 6C) were not optimal for entry, hence suggesting that the E1 cluster 5 blocks and
Fig 6. A dialog between E1 residues and the BL modulates virus entry and fusion. (A) Representation of the gt2
fusion cluster 5 (orange; dotted circle and linked by a bold line) as a putative mediator of E2 BL rearrangements and
fusogenic conformational changes. Putative movements of the E2 BL are indicated by dotted double arrows. Rotation
angles of the E2core structure and black cross are indicated as in Fig 3B. (B) Regions of interest to study the role of the
cluster 5 (orange) and design of the gt2 chimera. Three regions were defined as cluster 5 blocks. One is located on E1
(30 aa; Region 1) and two are located in E2 BLd (Region 2: E2 408–436, N terminal region; Region 3: E2 437–456, C
terminal region). (C-D) A dialog between E1 and the BL domain regulates virus entry. Infectious titers of HCVpp
(GFP i.u./ml, C) and HCVcc (FFU/ml, D) viral particles harboring J6 (black), 2b1 (white) and J6/2b1 E1E2 chimera.
Swapped regions (1, 2 or 3) are represented by white (2b1) or black (J6) boxes inserted into J6 or 2b1 linear
representations, respectively (bottom). Infectious titers were quantified 72h (HCVpp) or 4 days (HCVcc) post
infection of Huh7.5. (mean ± SD; n = 4); p<0.05.; ns non-significant. (E-F) A dialog between E1 and the BL domain
regulates membrane fusion. Cell-cell fusion induced by the different E1E2 chimera (as described in Fig 5J). HANA
(Influenza Hemagglutinin-Neuraminidase) envelope glycoproteins were used as positive control. Data are presented as
relative light unit (RLU) at pH5 (E) or as percentage of fusion (F) where pH7 RLU is considered as 100% fusion rate
for each chimera (mean ± SD; n = 3); p<0.05, p<0.01, p<0.001 ns non-significant. For panel (F), statistical
significances were determined for each experimental condition versus control condition (100%).
https://doi.org/10.1371/journal.ppat.1006908.g006
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the N-terminal half of the BL domain are involved in a dialog regulating virus entry. Produc-
tion and titration of HCVcc particles harboring these different chimeric envelopes confirmed
these results (Fig 6D, S15D Fig). Interestingly, 2b1-1/2 also displayed improved ability to
mediate cell-to-cell fusion (Fig 6E) as well as higher fusion efficiency at neutral pH than at
acidic pH (Fig 6F), suggesting that this chimera exhibited an E1E2 conformation already
primed for fusion at neutral pH. In contrast, J6-1/2 chimera did not increase J6 fusion effi-
ciency and abrogated E1E2 sensitivity to low pH at levels similar to those of 2b1 (Fig 6E and
6F). Altogether, consistently with BIS predictions, these results suggest that conserved inter-
plays between the central region of E1 and the N-amino-terminus region of the BL likely gov-
ern E1E2 fusogenic conformational states. Our results also support the maintenance of such
dialogs through coevolution as they appeared to be mediated by genotype-specific regions of
E1 and the BL.
BIS identify genotype 1 coevolving amino acids in E1 and the Stem region
that regulate HCV fusion
To extend our transfer between the bioinformatics identification of coevolving amino acid
clusters to the functional linkage of these domains, we tested the ability of BIS to pinpoint spe-
cific amino acids located in other regions than BL and furthermore, in the context of another
genotype than genotype 2 (studied above). For this purpose, we sought to challenge a gt1a
fusion cluster identified by BIS (Fusion cluster 5, S4–S6 Tables), which involved four residues
within E1 central region (position 78 and 113–115) and a domain of 10 amino acids (452–461)
within the Stem region. We employed two poorly divergent genotype 1a E1E2 sequences, H77
and A40, that displayed two E1 (SI/GM; position 112 and 117) and one E2 (D/N; position 462)
amino acid differences located at the borders of the gt1a fusion cluster 5 blocks (Fig 7A; S16A
Fig). Unlike J6 and 2b1, the level of functionality of H77 and A40 were relatively close (2.4x104
and 1.6x104 GFP i.u. per ml respectively) despite being significantly different (Fig 7B), hence
making it challenging to predict the influence of residue swaps on envelope functionality. H77
chimera harboring both swapped E1 and E2 A40 residues significantly impacted HCVpp
infectivity, although swapped E1 or E2 residues alone did not impact H77 functionality (Fig
7B) despite similar E1E2 expression and incorporation (Fig 7C). Importantly, H77 chimeras
harboring only the E1 or E2 A40 residues showed defect for cell-cell fusion compared to H77,
although fusion ability of the H77 chimera harboring both the E1 and E2 mutations were
enhanced (Fig 7D). Altogether, consistently with BIS predictions, our results suggest that these
E1 and E2 residues −and to larger extend the E1 central region and the E2 stem− are part of a
coevolving network that regulates the fusogenic properties of gt1a viral envelope.
Discussion
Flaviviridae are cause of many health concerns worldwide. A better understanding of the
molecular processes regulating the life cycle of these viruses is critical for the design of potent
anti-viral therapies. By taking advantage of the high-mutation rate of these viruses, coevolution
analysis represents a valuable approach to decrypt viral protein functional rearrangements and
provide basis for their inhibition. Here, we employed a recent coevolution analysis method,
BIS [22–24] to provide a proof of concept of such approach.
Coevolution signals detected within DENV E and Pr recapitulated several structural fea-
tures of DENV E/E-Pr protein complexes in different conformational states, hence highlight-
ing the structural accuracy of BIS predictions. Coevolution analysis of HCV E1E2 sequences
from several genotypes and sub-types led to the identification of several coevolution signals in
HCV E1E2 and suggested that E1 and E2 are strong coevolving partners that refold
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interdependently during fusion (Fig 8). Importantly, the E2 BL emerged as a key element of
these rearrangements that could mediate the transition of E1E2 complex from a pre-fusion to
a post-fusion conformation. We propose that during this transition, the endogenous E2 BL
packs with the front sheet of E2. Thus, a recombinant soluble BLd-H77 could compete with
the endogenous E2 BL and block HCV fusogenic rearrangements, then leading to inhibition of
membrane fusion (Fig 8). Such competition is consistent with the idea that E2 may harbor a
stretched pre-fusion structure exposing internal epitopes. The existence of other E2 structures
is also supported by the ability of neutralizing antibodies to target an epitope that is not
Fig 7. BIS uncovers a coevolving signal between E1 and the Stem region that regulate HCV fusion. (A) Position of
the three amino acid residues that differs between H77 (blue) and A40 (red) and are hypothesized to coevolve
according to BIS prediction (gt1a cluster 5). The three H77 amino acids will be replaced by A40 residues individually
or altogether to challenge BIS prediction. (B) Impact of the E1/Stem coevolution signal on HCV entry. Infectious titers
of HCVpp viral particles harboring H77 (blue), A40 (red) and H77/A40 E1E2 chimera were determined. Two E1 H77
residues (S112, I117), a single H77 E2 residue (D462) or both (S112, I117, D462) were introduced into E1E2 A40. The
different envelopes were incorporated at the surface of HCVpp, then used to infect Huh7.5. Infectious titers were
quantified 72h post infection by flow cytometry (mean ± SD; n = 3). p<0.05, ns non-significant. (C) H77/A40 E1 and
E2 chimera expression and incorporation onto HCVpp. Expression in transfected 293T cells (Cell lysates) and
incorporation onto concentrated pseudoparticles (Viral Pellets) of E1 and E2 from the different H77/A40 chimera.
Detection of E1 and E2 onto pseudoparticles harboring no envelope glycoproteins was used as negative control.
MLV-Capsid (CA) was detected to control equivalent HCVpp production between chimera. (D). Impact of the E1/
Stem coevolution signal on HCV fusion. LTRhiv-luciferase vector transduced 293T cells expressing the different E1E2
H77/A40 chimeric envelope glycoproteins were co-cultured with Tat-expressing Huh7.5 cells. Co-cultured cells were
exposed to an acid shock (pH5, orange) or not (pH7, red) and luciferase activities were determined 72h post-exposure.
Results are presented in relative light units (RLU) for each experimental condition (mean ± SD; n = 3). p<0.05,
p<0.001.
https://doi.org/10.1371/journal.ppat.1006908.g007
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Fig 8. BIS as a methodology to decrypt virus entry mechanisms. Schematic representation of the experimental approach
employed in this study, from BIS computational analysis to the design and challenge of a mechanistic model of viral fusion.
Following sequence analysis, matrix of E1E2 amino-acid coevolution were generated by BIS for different HCV genotypes.
Plotting of matrix coevolution networks onto E2core structure unveiled a potential scenario of E1 and E2 rearrangements
during HCV fusion, which involved the BL domain of E2. At the protein domain level, the construction of a soluble form of
the BL and the conduction of several experimental assays supported such hypothesis. In parallel, at the amino acid level, the
experimental validation of coevolution signals between specific residues of E1 and of the BL highlighted the critical role of
E1-BL networks in regulating fusogenic rearrangements (and more generally, the critical role of coevolving networks
between E1 and E2 C-terminal regions). Altogether, this approach allows us to propose a HCV fusion model where BL
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exposed in the E2core structure (i.e. aa305-324 [33]). Whether the entire BLd-H77 or specific
BL amino acids regions are sufficient to inhibit HCV fusion remain to be determined. How-
ever, a recent study aiming to screen E2-derived peptide inhibiting HCV infection did not
identify peptides within the BL [34], suggesting that a large fraction of the BL, instead of a spe-
cific amino acid region, is likely to be required to inhibit HCV entry. This hypothesis rein-
forces the idea of a physical, but not functional, competition between the endogenous BL and
BLd-H77. Our work also suggests that the E2 BL acts in close collaboration with E1 and that
these domains are probably in close proximity in E1E2 heterodimer. Indeed, E2core structure
is highly concealed by glycans at the exception of the BL [7]. This, combined with the fact that
E1 and BL do not seem to represent preferential targets of anti-HCV neutralizing antibodies,
suggests that the BL region and E1 may conceal respective epitopes. The critical interplay
between BL and E1 during fusion was also demonstrated at the amino acid level, as BIS was
able to accurately identify coevolution signals between specific residues of E1 and the BL that
tightly regulate HCV fusion (Fig 8).
By employing an original multi-disciplinary approach combining computational analysis
and experimental assays, our work sheds light on potentially important structural and func-
tional features of the HCV fusion mechanism. Although the clear roles of E1 and E2 during
the HCV fusion process still remain to be better defined through the structural resolution of
the E1E2 heterodimer at different pH, our work initiates a path toward an experimentally-sup-
ported model for HCV-cell fusion.
In this putative model, E1 would play the role of a fusion protein protruding onto the virus
surface whereas E2 would be a receptor binding protein and a fusion chaperone concealing E1
epitopes. Although E2core is a truncated E2 protein and may not exhibit full E2 properties,
E2core does not respond to pH variation [6]. This, combined with the fact that E2 does not
harbor fusion protein structural features, could suggest that E2 needs to be associated with E1
to undergo conformational changes and to chaperone E1 fusion-promoting rearrangements.
Interestingly, non-conserved E1 residues swapped between the J6 and 2b1 envelope (Fig 6)
were located at a very close proximity upstream of the putative E1 fusion peptide (CSA-
LYVGDLC) [11–16]. This result may suggest that the interaction of these E1 residues with E2
BL could participate to critical E1-E2 rearrangements leading to the fusion peptide insertion
into the endosomal membrane. Following receptor priming [35] and insertion of a putative E1
fusion peptide into the endosomal membrane, HCV fusion could be triggered by a fold-over
of the C-terminal domain of E1 toward its N-terminal domain. This rearrangement could be
mediated by E2 BL movements, or alternatively, could promote E2 BL movements. Overall,
this interdependent refolding would result in the packing of the BL and of the E2 C-terminal
region toward the E2 front sheet, and to the fusion of the host and viral membranes (Fig 8).
The Ig-fold β-sandwich structure of E2core has been proposed to display similarities with
domain III or B from class II fusion proteins [7]. By chaperoning E1 fold-over and membrane
fusion, our results support that E2 function could be related to a domain III-like, as recently
suggested [36]. Further structural studies aiming to resolve the full structure of the entire HCV
heterodimer in pre- and post-fusion conformations will be needed to decipher the integral
fusogenic rearrangements. Despite the fact that the structural differences detected for pesti-
virus E2 vs. HCV E2 glycoproteins makes unlikely that these viruses harbor a similar fusion
mechanism, it is possible that their E1 proteins could be derived from a common ancestor and
movements and E1 refolding are critical in the induction of E1E2 interdependent, fusogenic rearrangements. By being
applicable to other viral proteins and viruses, such approach provides opportunities to uncover undescribed viral-mediated
mechanisms and design innovative translational strategies for their inhibition.
https://doi.org/10.1371/journal.ppat.1006908.g008
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represent so far a potential new class of fusion protein as suggested by others [9,18]. Thus,
although the resolution of the E2core structure has undermined the role of E2 as a fusion pro-
tein, HCV fusion is likely mediated by two interdependent partners that display original struc-
tures and conformational changes. To our knowledge, our data provide unique evidence that a
component (in this case, the BL) derived from a receptor-binding protein with no fusion pep-
tide can modulate viral fusion rearrangements, hence highlighting HCV fusion as a unique
mechanism among known enveloped viruses.
A primary limitation of current coevolution analysis approaches relies on the availability of
a large number of sufficiently divergent evolutionarily-related sequences [37]. Such sets of
sequences constitute the bottleneck for today’s coevolution analysis methods. We have shown
previously that BIS can overcome these limitations and can address coevolution of conserved
sequences such as viral genotype sequences [22–24]. Consistently, we failed to detect coevolu-
tion signals within our sets of E1E2 sequences when employing other existing coevolution
methods (such as DCA, PSICOV and EVcouplings [38–40]), methods that we previously dis-
cussed in [23].
In strong contrast to our previous work [23] that was critical to understand the computa-
tional power of coevolution analysis applied to viral sequences, our current study goes beyond
the speculative and computational predictions and is fundamental is several ways. First,
exploring coevolution signals when no or little structural and functional information are avail-
able remain highly challenging and hamper the delineation of undescribed viral protein-medi-
ated processes. As coevolution signals imply structural or functional associations between
coevolving residues [22,23], our work shows that the BIS method is able to successfully high-
light E1E2 contacts that likely orchestrate structural rearrangements of the heterodimer com-
plex. In this respect, our work constitutes an important demonstration of BIS ability to decode
structural features of major conformational change in proteins families characterized by few
and conserved sequences. Hence, our work provides evidence that computational analysis of
coevolution with BIS can be fruitfully used to find direct (and possibly indirect) contacts
between proteins where the three-dimensional structure and rearrangements of protein com-
plexes are not known. Second, it demonstrates that coevolution analysis can highlight the exis-
tence of conformational changes in proteins through pairs of coevolving residues that are not
in contact in the known crystal structure. Many of the coevolution analysis tools developed in
recent years (such as DCA and DCA-like approaches) are detecting “direct contacts” and jus-
tify their success by using the 3D crystal as their evidence of true positive predictions. In our
study, we show that this idea only represents a part of the truth. Proteins are more complex
systems, undergoing different structural conformations during their lifetime, and that evolu-
tionary signals code not only for direct interaction but also for intermediate folding states and
alternative structural conformations. Third, we advance in the comprehension of how compu-
tational techniques can be used to help revealing protein “contacts” that are biologically inter-
esting, within and among structures. Finally, we provide experimental evidence of the
biological significance of the coevolution signals for viral genotype sequences, hence allowing
for a rapid identification of critical residue contacts regulating protein functions and
conformations.
Beyond uncovering important features of the HCV fusion mechanism, our study provides
altogether a proof of concept that coevolution can be successfully harnessed to decrypt viral
protein rearrangements and interactions, as well as to expand our knowledge of viral proteins-
mediated biological processes. Virus entry mechanisms and envelope glycoproteins conserved
epitopes represent valuable targets for the development of drugs and innovative vaccine strate-
gies against challenging human pathogens [41–46]. By unscrambling key protein interactions
or rearrangements, our work demonstrates that coevolution predictions can be of considerable
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value for stimulating a fast-tracked design and screening of innovative translational
approaches and antiviral strategies unimpeded by virus plasticity.
Materials and methods
Ethics statement
Experiments were performed in accordance with the EU guidelines (Directive 2010/63/EU) on
approval of the protocols by the local ethical committee (Authorization Agreement C2EA-15;
Ethic commitee: Comite´ d’Evaluation Commun au Centre Le´on Be´rard, à l’Animalerie de
transit de l’ENS, au PBES et au laboratoire P4 (CECCAPP), Lyon, France.
Cell lines, reagents and biological materials
Human Huh-7.5 (kind gift of C. Rice, Rockefeller University, NY), BRL3A rat hepatoma
(ATCC CRL-1442), and 293T kidney (ATCC CRL-1573) cells were grown in Dulbecco’s mod-
ified Eagle’s medium (DMEM) supplemented with 10% fetal calf serum (Invitrogen). Primary
human hepatocytes (PHH; BD Biosciences) were centrifuged using a F-12 HAM medium
(Sigma) and seeded overnight in collagen-coated 48 well plate (1x105 cells/well) into Gentest
seeding medium (BD Biosciences) completed with 5% FCS. The next morning, PHH were
washed and cultured with the culture medium for PHH William’s E medium (W4128, Sigma)
supplemented with 7,5% BSA, 1% ITS (insulin transferrin selenium, Gibco), 10-7M of Dexa-
methasone (Sigma), 1% of non-essential amino acids (Gibco), 1% of Glutamax (Gibco) and
1% Penicillin-Streptomycin solution (Gibco). Sera containing HCV particles were obtained
from a gt1b infected patient (Hoˆpitaux Universitaires de Strasbourg, Strasbourg, France) and
were subsequently amplified in uPA-SCID humanized liver mice. Viral loads (RNA copies
number/ml) were determined by RT-qPCR using a clinical diagnostic kit (Abbot).
Antibodies
The rat anti-E2 clone 3/11 [47], the mouse anti-E2 AP33 (Clayton et al., 2002) and the confor-
mational mouse anti-HCV E2 H53 [48] are kind gifts from J. McKeating (University of Bir-
mingham, UK), Arvin Patel (MRC—University of Glasgow Centre for Virus Research,
Glasgow, UK) and J. Dubuisson (Institut Pasteur de Lille, FR) respectively. AR3B [32] and
AR4A [30] antibody are a kind gift from Mansun Law (The Script research institute, San
Diego, USA). MLV Capsid was detected by a goat anti-MLV-CA antibody anti-p30 (Viromed).
HCVcc foci forming units were stained with a mouse anti-HCV NS5A antibody 9E10 [49], a
kind gift of C. Rice (Rockefeller University, NY, USA). Human CD81 were detected with JS81
mAb (BD Biosciences), human SRB1 with CLA-1 mAb (BD Pharmingen), human Claudin-1
with the MAB4618 mAb (R&D Syst.) and human Occludin with an anti-Occludin mAb target-
ing the C-terminal region of the protein (Laboratories Inc.). A Mouse anti-Human IgG2 anti-
body targeting human IgG2 hinge region (Novus Biological) was used to quantify BLd-tm
expression at cell surface. A rabbit 6His-tag antibody (Pierce antibody) was used to detect solu-
ble E2 and BLd-H77 6His-tag.
BLd-H77 construction
In order to construct a relevant BLd soluble peptide derived from a genotype 1a sequence, we
took into account the BL borders previously suggested (Fig 3B, see also reference [7]), but also
aimed to refine these borders using the locations of BIS coevolution networks of genotype 1a.
Indeed, BIS suggested that a 15 amino acids extension from residue 390 to 405, classified previ-
ously as an undefined domain [7] between the central Ig scaffold and the E2 BL, contained
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blocks (S4 Fig, block 7–1) that coevolve with another region of the BL (block 7–2), forming
altogether a fusion cluster (cluster 7). Hence, in order to rigorously challenge BIS predictions
that suggested a potential redefinition of the BL, we constructed a soluble BLd peptide from
residue 390 to 460. Hence, DNA sequence of HCV E2 coding for the residues 390 to 640 was
amplified from a genotype 1a envelope H77 (AF009606) cDNA sequence. This sequence was
subcloned into a phCMV plasmid to fuse the last 18 amino acids from the C-term part of HCV
core that act as a signal peptide, and a CH3-terminal 6 Histidine-tag was added. The resulting
peptide of 77 amino acids (71+6) was then named as BLd-H77.
BLd-H77 production, purification and analysis
BLd-H77 was expressed in 293T following transient transfection and purified from cell culture
supernatant (OptiMEM) by fast protein liquid chromatography on a Superdex G-75 gel filtra-
tion column (GE Healthcare). BLd-H77 was re-suspended in 1XPBS. The concentration of
purified BLd-H77 peptides was determined by absorption at 205 nm. The mass of BLd-H77
peptide was measured by ESI mass spectrometry using a Finnigan LCQ ion trap mass spec-
trometer (Thermo Electron Corporation). Analysis by SDS-PAGE electrophoresis was per-
formed using a standard Tris–glycine system and 11% acrylamide gels, in reducing or non-
reducing condition. Electrophoresis was followed by either coomasie blue staining or western
immunoblotting with an anti His tag antibody.
BLd-tm construction, expression and transduction
An anchored form of BLd-H77 was engineered by adding a hinge region (human IgG2) and
the transmembrane domain of the CD34 protein to the E2 BLd. The construct, named BLd-
tm, was then inserted into Gae-SFFV-IRES backbone harboring selectable marker gene P140K
MGMT. A similar construct, but encoding for a HIV-1 gp41 fusion inhibitor peptide [50],
namely C46, was used as a control. Construct details are available upon request. Lentiviral vec-
tors transducing BLd-tm or C46 were produced from 293T cells. Stable expression in Huh-7.5
was obtained by transduction with vector particle-containing supernatants of 293T producer
cells, followed by selection of O6-benzylguanine and BCNU. BLd-tm expression in Huh-7 cells
was quantified by FACS analysis using a mouse anti human IgG2 and an anti-mouse APC
antibody.
Proteins expression staining
BRL cells expressing CD81 or SRBI were washed and stained for 1h at 4˚C with a mouse anti-
human IgG2 antibody (for detection of C46 and BLd-tm), an anti-CD81 (JS81) and with an
anti-human SR-BI (CLA-1) respectively. Cells were then washed and incubated with a second-
ary anti-mouse or rat APC antibody for 1h at 4˚C. Cell surface expression levels were then
quantified by flow cytometry (FACS CANTO II–BD Biosciences). For HCV receptor detection
on Huh7.5 and Huh7.5-BLd-tm cells, cells were fixed with 2% formaldehyde for 20 min at
room temperature and washed. For Occludin staining, cells were permeabilized with Perm/
Wash Buffer (BD Biosciences) for 15 min at 4˚C prior staining. Human CD81 was stained
with JS81 mAb, human SRBI with CLA-1 mAb, human Claudin-1 with the MAB4618 and
human Occludin with an anti-Occludin mAb targeting the human Occludin C-terminal
region. To characterize the effect of BLd-H77 on HCV receptor expression, Huh7.5 were incu-
bated overnight with BLd-H77 (50μg/ml) prior staining.
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Production of HCVpp, infection and neutralization assay
HCVpp were produced as previously described [21,51] from 293T cells cotransfected with a
murine leukemia virus (MLV) Gag-Pol packaging construct, an MLV-based transfer vector
encoding the green fluorescent protein, and E1E2 envelope expression constructs H77
(AF009606), A40 (unreferenced), UKN1B 12.6 (AY734975), UKN2A 2.4 (AY734979), JFH-1
(AB047639), J6 (AF177036), UKN2B 2.8 (AY734983), UKN3A 1.9(AY734985), UKN4 21.16
(AY734987), UKN5 14.4 (AY785283), HK 6A-2.1 (FJ230883) or control envelope HA-NA
(CY077420) and VSV-G (AJ318514). All chimeric J6/2b1 E1E2 heterodimers were constructed
by molecular cloning, PCR and/or digestion between the genotype 2a envelope J6 (AF177036)
and a genotype 2b envelope UKN-2b1 (unreferenced). All chimeric H77/A40 E1E2 heterodi-
mers were constructed using a similar strategy between the genotype 1a envelope H77 (AF00
9606) and A40 (unreferenced, but previously employed [21]). 72 to 96h following infection,
percentage of infected cells was quantified by FACS Canto II or LSRII (BD Biosciences) to
quantify GFP expression. For BLd-H77 dose-dependent neutralization assay, HCVpp H77 or
VSVGpp were pre-incubated with different concentrations of BLd-H77 or with PBS for 1h at
room temperature and were then used to infect Huh7.5. For the time-course neutralization
assay, Huh7.5 were infected with HCVpp H77 for 4h prior washing. PBS, BLd-H77 (50 μg/
ml), Bafylomycin A1 (20nM) or AR4A (25 μg/ml) were added into cell supernatant for 1h
prior infection, during infection or after infection. Percentage of infected cells was determined
72h following infection. For HCVpp co-neutralization assay, HCVpp H77 pseudoparticles
were pre-incubated for 1h at room temperature with BLd-H77 alone (35 or 50 μg/ml), AR4A
alone (2 or 17 μg/ml) or with both BLd-H77 and AR4A (35 and 2 μg/ml, or 35 and 17 μg/ml).
Pre-mixes were then used to infect Huh7.5 and media was changed 6h post infection. GFP
intracellular levels were quantified 4 days post infection by flow cytometry. For HCVpp post-
binding neutralization assay, HCVpp-H77 pseudoparticles were incubated with Huh7.5 in
presence of BLd-H77 (50 μg/ml) or AR4A (25μg/ml) for 1h at 4˚C (binding), for 4h at 37˚C
following binding (entry), or for 72h following entry (post-entry). As control, Huh7.5 were
incubated and infected with HCVpp-H77 in a similar manner but not treated with BLd-H77
or AR4A.GFP intracellular levels and related percentage of infection were then quantified by
flow cytometry. For HCVpp containment assay on Huh7.5-BLd-tm, Huh7.5 or Huh7.5-BLd-
tm were infected or not with HCVpp H77 for 5h. Then, cells were washed and E2 cell surface
expression was determined by flow cytometry following staining using the anti-E2 H53 anti-
body and a secondary anti-mouse APC antibody. Huh7.5 and Huh7.5-BLd-tm were infected
similarly and GFP expression of infected cells was analyzed 72h post-infection.
Expression and incorporation of E1E2 glycoproteins onto HCVpp
Transfected 293T cells were lysed and nuclei were removed by centrifugation at 12 000 rpm
for 10 min. HCVpps were purified and concentrated from the cell culture medium by ultra-
centrifugation at 82,000xg for 1h 45 min through a 20% sucrose cushion. Cell lysates and viral
pellets were subjected to western blot analysis using 3/11 anti-E2 antibody and an anti-
MLV-CA antibody as described previously [21].
HCVcc production and infection
Plasmid pFK H77/JFH1/HQL (kind gift of R. Bartenschlager), termed as H77/JFH-1, display-
ing HCV genome with adaptive mutations (Y835H in NS2, K1402Q in NS3, and V2440L in
NS5A) and harboring H77 sequence derived from the BLd-H77peptide, as well as plasmid
pFKi389-Venus-Jc1, termed as Jc1, (an intra-genotypic recombinant between J6-CF sequence
(AF177036) and JFH1 sequence) were used to produce and electroporate into Huh7.5 the
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respective H77/JFH-1 and JC1 viral RNAs as described previously [21]. Huh7.5 cells, Huh7.5-
BLd-tm or Huh7.5-C46 were infected with different dilutions of culture supernatants har-
vested at 24h, 48h and 72h post electroporation. Four days post-infection, cells were fixed with
EtOH 100% and foci forming units (FFUs) were visualized after NS5A immunostaining as
described previously [21]. For BLd-H77 dose-dependent neutralization assay, HCVcc particles
were pre-incubated with different concentrations of BLd-H77 or with PBS for 1h at room tem-
perature and were then used to infect Huh7.5. For time-course neutralization assay, Huh7.5
were infected with HCVcc for 4h prior washing. PBS or BLd-H77 (35 μg/ml) were added into
cell supernatant for 1h prior infection, during infection or after infection. FFU/ ml were deter-
mined 4 days post-infection. To construct HCVcc particles harboring 2b1, J6-1/2, 2b1-1/2 or
2b1-1/3 envelope, we inserted by molecular cloning the related envelope into the pFKi389-Ve-
nus-Jc1 molecular clone, that initially encodes for J6 envelope. Viral RNAs were electroporated
into Huh7.5 as described above. At 72h post electroporation, cell culture supernatants were tit-
tered and used to infect naïve Huh7.5. Number of foci forming units per ml were determined
4 days post infection as described above. In parallel, viral RNA were extracted from electropo-
rated cell culture supernatants at 72h post (ZR viral RNA kit, Zymo). HCV viral RNA copy
number was quantified by one-step reverse transcription-PCR (RT-PCR) using MultiCode-
RTx Real-Time PCR (Luminex) according to manufacturer’instructions and run on a Step
One Plus quantitative PCR machine (Life Technologies). Data were analyzed using the Multi-
Code Analysis Software v1.6.5 (Luminex). The following primers were used for the detection
of HCV RNA: GCTCACGGACCTTTCA (sense) and GGCTCCATCTTAGCCC (antisense).
Huh7.5-BLd-tm infection assay
H77/JFH1 virus was used to infect Huh7.5 and Huh7.5-BLd-tm (m.o.i. 0,1). At day 1, 3 and 5
post infection, cells were fixed with 2% formaldehyde for 20 min at room temperature, washed
and permeabilized with Perm/Wash Buffer (BD Biosciences) for 15 min at 4˚C. NS5A expres-
sion levels were then quantified using anti-NS5A antibody 9E10 by flow cytometry (FACS
CANTO II–BD Biosciences). In parallel, cell supernatants were harvested at each time point,
filtered and used to infect naïve Huh7.5. 72h post infections, infectious titers (FFU/ml) of cell
supernatant were determined as described above.
Infection-dilution assay
HCVpp H77 and H77/JFH-1 HCVcc particles were preincubated for 1h at room temperature
with PBS or BLd-H77 (50 μg/ml or 35 μg/ml respectively). Then, BLd-H77 and concentrated
viral particles were diluted (1/5) with cell culture media or not prior infection of Huh7.5. 4
days post infection, percentages of GFP-positive cells were determined by flow cytometry and
FFUs/ml were determined by NS5A immunostaining as described above.
Cell-to-cell transmission assay
H77/JFH-1 were used to infect Huh7.5 for 4h at 37˚C (m.o.i. 0,05). After washing, cells were
incubated with anti-E2 antibody AP33 (25μg/ml) alone, or mixed with BLd-H77 (35μg/ml), or
with PBS. 72h post infection, cells were fixed and numbers of cell per foci for each condition
were quantified through NS5A immunostaining as described above.
PHH infection and neutralization assay
PHH were washed and infected by JC1 HCVcc virus at different m.o.i. (0,005; 0,001; 0,05; 0,1).
4 days post infection, cell culture supernatants were harvested and used to infect naïve Huh7.5.
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Infectious titers were revealed through NS5A immunostaining 4 days post infection as
described above. Indirect titrations were performed as infected PHH were poorly detectable
through NS5A immunostaining, making the indirect titration the only accurate method to
quantify the amount of infectious viral particles (and not physical viral particles) in a PHH-cell
culture supernatant. For neutralization assay, JC1 virus or JC1-derived HCVpc were pre-incu-
bated with BLd-H77 (10, 20 and 40 μg/ml) or with PBS for 1h prior PHH (m.o.i. 0,05) or
Huh7.5 infection respectively (m.o.i. 0,01 and 0,02). 4 days post infection, infectious titers of
PHH cell culture supernatants were determined by infecting Huh7.5 as described above. In
parallel, infectious titers of JC1-derived HCVpc following Huh7.5 infection were quantified as
described above. Sera containing HCV particles were used to infect PHH at a m.o.i. of 0,1 fol-
lowing BLd-H77 (30 μg/ml) or PBS preincubation for 1h at room temperature. 4 days post
infection, cell culture supernatants were harvested and viral loads (RNA copies number/ml)
were determined by RT-qPCR using a clinical diagnostic kit (Abbot Real Time™ HCV assay)
with a limit of quantification (LOQ) of 12 IU/mL (i.e. 51.6 HCV RNA copies/ml). Given a
serum dilution of 1:100 in PBS, LOQ = 5160 HCV RNA copies/ml.
Establishment of BRL cell lines expressing human CD81 and human SR-BI
Retroviral vectors expressing human CD81 (NM_004356) and SR-BI (Z22555) were described
previously [52]. Retroviral vectors containing these cDNAs were produced from 293T cells as
VSV-G pseudotyped particles as described previously [53,54]. Stable expression of either
receptor in BRL cells was obtained as described previously [52].
E2 and HCVpp binding assay
Binding assays were performed as described previously [21]. Briefly, 50μl of concentrated virus
(100x) or 100 ul of concentrated soluble E2 (100x) were pre-incubated with BLd-H77 (50 μg/
ml) or with PBS for 1h at room temperature. Then, pseudoparticles or soluble E2 were mixed
with Huh7.5, BRL, BRL-CD81 or BRL-human SR-BI in presence of 0.1% sodium azide for 1h
at 37˚C. Cells were then washed with PBFA (PBS, 2% fetal bovine serum, and 0.1% sodium
azide). Bound viruses were detected using the mouse H53 anti-HCV E2 antibody and soluble
E2 was detected using either the H53 antibody or a rabbit 6His-tag antibody for 1h at 4˚C.
After washing, primary antibodies were quantified by flow cytometry (FACS Canto II, BD Bio-
sciences) using APC goat anti-mouse immunoglobulin-G. In parallel, concentrated HCVpp
were pre-incubated with 50 μg/ml of BLd-H77 and used to infect Huh7.5 in order to verify the
neutralizing effect of BLd-H77 on the entry of concentrated HCVpp. For BLd-H77 binding
assay, BLd-H77 (50 μg/ml) or PBS were mixed with Huh7.5 for 1h at 37˚C prior 6His-tag
staining using a rabbit 6His-tag antibody.
Binding enhancement assay
Concentrated soluble E2 (100x; 100 or 250 μl) were mixed with equivalent number of Huh7.5
or Huh7.5-BLd-tm (2x105 or 5x105 cells) in presence of 0.1% sodium azide for 1h at 37˚C.
After washing, bound soluble E2 were detected using anti-E2 H53 antibody as described
above. Levels of binding enhancement were determined relatively to the basal E2 binding on
naïve Huh7.5. For HCVpp binding enhancement assay, 1x105 Huh7.5 cells or Huh7.5-BLd-tm
were infected with HCVpp for 4 hours. Cells were then trypsinized and washed with PBFA
(PBS, 2% fetal bovine serum, and 0.1% sodium azide). Bound viruses were quantified by flow
cytometry (FACS Canto II, BD Biosciences) following cell staining with the mouse H53 anti-
HCV E2 and an APC goat anti-mouse immunoglobulin-G.
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HCVcc binding assay
JC1 HCVcc particles (5x104 i.u.) were pre-incubated with BLd-H77 (35 μg/ml), Heparine
(250 μg/ml) or with PBS for one hour at 37˚C. Viral particles were then mixed with 1x105
Huh7.5 cells for 2h at 4˚C. After 3 washings, cells were lysed using the RLT Buffer (QIAGEN)
complemented with β-mercaptoethanol. Total RNAs were then extracted using the RNeasy
mini kit (QIAGEN) as recommended by the manufacturer. Extracted RNAs were reverse tran-
scribed using the iScript cDNA synthesis kit (Bio-Rad) and HCV viral RNA (5-CTTCACGCA
GAAAGCGCCTA and 5-CAAGCGCCCTATCAGGCAGT) and human GAPDH (5- GAAG
GTGAAGGTCGGAGTC and 5- GAAGATGGTGATGGGATTTC) were then quantified by
qPCR using the FastStart Universal SYBR Green Master kit (Roche Applied Science) on an
Step One Plus quantitative PCR machine (Life Technologies). Cell-associated viral RNA copies
were normalized on human GAPDH expression for each sample.
ELISA assay
96-well plates (Corning) were coated overnight with different amounts of a mouse IgG isotype
(10ng and 100ng; Abcam), anti-E2 antibody AR3B [32] (10 and 100ng), and BLd-H77 (10, 100
and 250ng). The next day, following a one-hour incubation step with a SuperBlock blocking
buffer (Thermo Scientific) to prevent non-specific binding, each coating condition was incu-
bated with 10ng of sE2 or not. Interactions were revealed using a rat anti-E2 antibody 3/11
[47] or a rat IgG isotype, then followed by an incubation with an anti-rat HRP antibody
(Biorad). Optical density signals at 450 nm were then assessed using a TriStar Multimode
Microplate reader (Berthold).
Mice and primary human hepatocytes (PHH) transplantation
FRG (Fah–/–Rag2–/–Il2rg–/–) mice (mixed background: C57BL/6 and 129Sv) were housed in
our animal facility (Plateau de Biologie Experimentale de la Souris, PBES, Lyon, France).
Because of their lethal phenotype, mice are maintained on 8 mg/l of NTBC (nitro-4-trifluoro-
methylbenzoylcyclohexanedione) in the drinking water. 48h prior the engraftment, adult (6–
10 weeks old) mice were injected intravenously with 2x109 p.f.u. of an adenoviral vector
encoding the uPA transgene. 7x105 to 1x106 PHH (BD Biosciences) were injected intraspleni-
cally as previously described [55]. Immediately after engraftment, the NTBC was progressively
withdrawn as follow: 2 days at 10% of colony maintenance concentration, then 2 days at 5%, 2
days at 2.5%, then the NTBC was completely removed. During the phase without NTBC, mice
were weighted every two days. After 2–6 weeks, mice with clinical symptoms (lethargy,
hunched posture) or severe weight loss (>15%) were put again on NTBC for 3 days before sec-
ond withdrawal (cycling). Cycling was repeated until clinical symptoms resolved. In order to
prevent the development of a murine hepatocellular carcinoma, highly reconstituted mice
selected for infectious experiments were subjected to further NTBC treatment (3–4 weeks w/o
NTBC and 3 days with 100%).
FRG mice serological analyses
Blood from transplanted mice and controls were collected every 2–4 weeks after engraftment
by retro orbital puncture. Sera were sent to a diagnostic laboratory for quantification of
human Albumin (Cobas C501 analyzer, ROCHE).
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HCV infection of humanized liver FRG mice
Highly reconstituted mice (HSA >15mg/ml) were infected with JC1 HCVcc particles inocula
(105 i.u.) or with patient-derived HCV particles (5x104 i.u.) via intraperitoneal route. Mice sera
were collected at day 7 and day 14 post-infection by retro-orbital bleeding. At day 21, mice
were sacrificed, sera were collected and levels of human albumin were determined (Cobas
C501 analyzer, ROCHE). JC1 infectious titers in mice sera were determined through infection
of Huh7.5 with different dilutions of sera as described above. In parallel, for HCV particle con-
taining sera, viral load was determined by RT-qPCR using a clinical diagnostic kit (Abbot Real
Time™ HCV assay) with a limit of quantification (LOQ) of 12 IU/mL (i.e 51.6 HCV RNA cop-
ies/ml). Given a serum dilution of 1:100 in PBS, LOQ = 5160 HCV RNA copies/ml.
In vivo HCV inhibition assay
A first cohort of 11 mice was attributed for an in vivo inhibition assay of JC1 infection (9 mice
+ 2 negative controls; one non-infected and one non-engrafted). 7 mice were treated under a
prophylactic protocol with PBS (4 mice) or with 30 μg (3 mice) of BLd-H77. Mice were treated
via intra-peritoneal route one day prior infection, and at day 1, 7 and/or 14 post-infection
infection. For all the mice, sera were harvested and viral titers were quantified at day 7, 14 and
during sacrifice 21 post infection. A second independent cohort of 7 mice was attributed for
another in vivo inhibition assay of JC1 infection (5 mice + 2 negative control). Here, JC1 infec-
tion was challenged with a dose of 150μg of BLd-H77 (2 mice) or with PBS (3 mice) under a
prophylactic protocol similar as described above. A cohort of 14 mice (12 mice + 2 negative
control) was attributed for an in vivo inhibition assay of serum-derived HCV particles infec-
tion, challenged with one dose of BLd-H77 (150 μg, 5 mice) or with PBS (7 mice) under a pro-
phylactic protocol similarly to what has been described above. Serum-derived HCV particles
viral load were determined as described above. Following sacrifice, the level of human Albu-
min was quantified for each untreated and treated mice in order to ensure that HCV infection
inhibition was not due to a decrease of liver humanization caused by BLd-H77.
Cell-cell fusion assay
Cell-cell fusion assays were performed as described previously [13,19]. Briefly, HEK-293T cells
(2.5x105 cells/well seeded in six-well tissue culture dishes 24 h before transfection) were co-
transfected using calcium phosphate reagent with a HCV (H77, J6, 2b1 or J6/2b1 chimera) or
VSV-G envelope encoding-plasmids and with an HIV-1 LTR (long terminal repeat) luciferase
reporter plasmid. After 12h, transfected HEK-293T cells were detached with versene (0.53 mM
EDTA; Invitrogen) and co-cultured (5x104 cells/well) with Huh-7-Tat indicator cells
(5.104cells/well) in a 24-well plate. After 24 h, the cells were washed with serum free DMEM,
incubated for 3 min in either pH 7 or pH 5 buffer (130 mM NaCl, 15 mM sodium citrate, 10
mM Mes and 5 mM Hepes) and then washed three times with serum free DMEM. The lucifer-
ase activity was measured 72 h later using a luciferase assay kit according to the manufacturer’s
instructions (Promega). For fusion neutralization assay, coculture were washed, pre-incubated
with BLd-H77 (50μg/ml) or with PBS for 1h at 37˚C prior a second washing and exposure to
pH buffer. Alternatively, co-cultured cells pre-treated by BLd-H77 or PBS were incubated for
an extension of 24h following pH shock by BLd-H77 (50μg/ml) or PBS.
Liposomes fusion assays
HCVpp/liposome lipid mixing was performed as previously described [21,56]. R18-labeled
liposomes were obtained by mixing octa-decyl rhodamine B chloride (R18; Molecular Probes)
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and lipids (phosphatidylcholine and cholesterol; Aventi) and mixed with 40 μl of concentrated
HCV pseudoparticles (non-enveloped HCVpp, HCVpp-H77 and HCVpp harboring the
fusion defective envelope E140/E2H77 previously characterized [21]) or retroviral particles
pseudotyped with Influenza Hemagglutinin-Neuraminidase (HANApp), all diluted in PBS
(pH 7.4) within a 37˚C thermostable 96-well plate. After pH decrease to 5 (acidification),
dequenching of R18 due to lipid mixing between HCVpp and liposomes were recorded on a
micro-plate fluorometer (InfiniteM1000 Tecan Group Ltd) for a period of 5 to 20min with an
excitation wavelength (λexc) at 560 nm and an emission wavelength (λem) at 590 nm. Maxi-
mal R18 quenching was measured after the disruption of liposomes by the addition of 0.1%
TritonX-100. For fusion-neutralization assays, pseudoparticles were pre-incubated with differ-
ent doses of BLd-H77 or with PBS for 1h prior incubation with liposomes and acidification.
Structural analysis
Structural analysis of Dengue E pre-fusion structure (PDB 1K4R), E-Pr complex structure
(3C6E), E post-fusion structure (1OK8) and E2core structure (4MWF) were realized using
Chimera software [57] (UCSF).
Statistical analysis
GraphPad Prism software (version 6) was used for statistical analysis. Statistics were calculated
using Student’ t test and/or two-way ANOVA when appropriate. (p<0.05, p<0.01,
p<0.001).
Protein sequence alignment
Protein amino acid sequence alignments were realized using ClusterX2.1 and rendered as
Post-script format.
Computational coevolution analysis using BIS
The BIS methodology and related-coevolution signal analysis are described in details in refer-
ence [22], [23] and [24]. Applicability of BIS for detecting coevolution signals in viral
sequences is specifically described in reference [23].
Attribution of putative functions to E1E2 clusters in S4 Table and S7 Table
Literature describing amino acids mutations within E1E2 sequences impacting E1E2 folding/
heterodimerization, E1E2 binding to cellular receptors or E1E2 fusion was used as references
to attribute functions to clusters mapping specific regions within E1E2 sequences. The refer-
ences used were the following: Folding/Heterodimerization [19,27,28,58–60], Viral binding
site conformation [19,20,26,60–66] and Fusion [11,13,19–21,27,67].
Supporting information
S1 Text. Detailed analysis of genotype 1a HCV E1E2 clusters.
(DOCX)
S2 Text. Detailed analysis of genotype 2 HCV E1E2 clusters.
(DOCX)
S1 Table. Clusters of coevolving residues identified by BIS in DENV envelope glycoprotein
E and PrM sequences of serotype 2. 17 amino acids sequences of DENV E and PrM serotype
2 were aligned and 14 Clusters were identified by BIS. Clusters are computed with the BIS
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coevolution analysis method [22–24] and they correspond to maximum scores (symmetricity
and environmental scores are set to 1, and the number of admissible exceptions to 0 or 1). For
each cluster, the positions of the different coevolving residues or blocks (the initial and final
position of each block is reported), and corresponding p-value, are indicated. BIS considered
the first amino-acid of PrM as position 1 for all the analyzed sequences. For each cluster, the
frequency of its most conserved residues is given (“conservation score”). It should be noted
that in BIS, when scores are maximal (that is, set to 1 as for this analysis), all blocks/residues in
a cluster display the same amino-acid distribution (See the identical distribution of residues
for the two coevolving positions in the alignment of S1 Fig as an example).
(DOCX)
S2 Table. Clusters of coevolving residues identified by BIS in DENV envelope glycoprotein
E sequences of serotype 2. Clusters are computed with the BIS coevolution analysis method
[22–24] and they correspond to maximum scores (symmetricity and environmental scores are
set to 1, and the number of admissible exceptions to 0 or 1). For each cluster, the positions of
the different coevolving residues or blocks (the initial and final position of each block is
reported) and the corresponding p-value are indicated. BIS considered the first amino-acid of
E as position 1 for all the analyzed sequences. For each cluster, the frequency of its most con-
served residues is given (“conservation score”). It should be noted that in BIS, when scores are
maximal (that is, set to 1 as for this analysis), all blocks/residues in a cluster display the same
amino-acid distribution (See the identical distribution of residues for the two coevolving posi-
tions in the alignment of S1 Fig as an example).
(DOCX)
S3 Table. BIS coevolution analysis of HCV E1E2 sequences. Ten groups of sequences were
assembled and analyzed independently with the BIS method. Groups were constituted of E1E2
sequences from HCV types and sub-types from genotype 1a to 6a. Groups of sequences from
genotypes 1 and 2 were constituted by pools of sequences from subtypes 1a and 1b (50
sequences) and sequences of genotypes 2a and 2b (30 sequences). Total numbers of detected
clusters for each genotype and sub-type is reported, as well as the number of statistically signif-
icant clusters among them (when p<0.05). For each group of sequence, we also report the
number of statistically significant clusters only involving E1 positions (“intra-E1”), the number
of clusters only involving E2 positions (“intra-E2”), and the number of clusters across E1 and
E2 (“inter-E1-E2”). The assignment of a given cluster block to E1 or E2 was determined by
mapping the reference genome sequence of genotype 1b (accession: AJ238799) to the multiple
sequence alignment, for each genotype. E1 and E2 were identified on AJ238799 at positions
192–383 and 384–746, respectively. Note however that residue positions displayed in S4
Table, S7 Table and in the related HCV webserver (http://www.lcqb.upmc.fr/HCVenv/
HCVenv.html) are specific to each genotype and set of patient sequences analyzed.
(DOCX)
S4 Table. Clusters of coevolving residues identified by BIS in HCV E1E2 sequences of
genotype 1a. Clusters are computed with the BIS analysis method similarly to S1 Table. Note
that residue positions displayed in this table are specific to the set of patient sequences ana-
lyzed. Hence, nucleotide gaps generated during the analysis of the patient sequences by BIS
were taken into account when plotting gt1a clusters into a gt1a reference E1E2 reference (H77,
AF009606; (S4 Fig) and into gt1a E2core structure (S5 Fig).
(DOCX)
S5 Table. List of Genotype 1a cluster blocks mapped on E1E2 references sequences (H77,
AF009606). For each block, the initial and final position of the block predicted by BIS and the
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name of the cluster it belongs to are given. Blocks from each cluster are numerated from 1 to x
(Block N˚) to easily identify their position on the E1E2 sequences in S4 Fig, where each block
is referenced as follow: “Cluster ID-Block N˚”.
(DOCX)
S6 Table. Putative functions of genotype 1a E1E2 coevolution clusters. We aligned 25 E1E2
amino acids sequences of HCV genotype 1a and identified using BIS method 16 clusters (S3
Fig; S4 Table). Genotype 1a clusters harboring blocks that mapped residues previously
reported in the literature to have a specific function (S4 Fig) are classified. The known role(s)
are indicated: Folding or heterodimerization (blue), viral binding site conformation (green) or
fusion mechanism (red). According to these roles, clusters are categorized into three different
categories: structural (Folding, heterodimerization and viral binding site conformation),
fusion or multifunctional cluster. Clusters harboring blocks that did not map any residues
with a previously reported function were classified as clusters with “undefined role.
(DOCX)
S7 Table. Clusters of coevolving residues identified by BIS in HCV E1E2 sequences of
genotype 2. Clusters are computed with the BIS analysis method similarly to S1 Table. Note
that residue positions displayed in this table are specific to the set of patient sequences ana-
lyzed. Hence, nucleotide gaps generated during the analysis of the patient sequences by BIS, as
well as gaps between gt1a and gt2 sequences, were taken into account when plotting gt2 clus-
ters into a gt2 reference E1E2 reference (JFH-1, AB047639; S7 Fig) and into gt1a E2core struc-
ture (S8 Fig).
(DOCX)
S8 Table. List of genotype 2 cluster blocks mapped on the E1E2 reference sequences (JFH-
1; AB047639). For each block, the initial and final position of the block predicted by BIS and
the name of the cluster it belongs to are given. Blocks from each cluster are numerated from 1
to x (Block N˚) to easily identify their position on the E1E2 sequences in S7 Fig, where each
block is referenced as follow: “Cluster ID-Block N˚”.
(DOCX)
S9 Table. Putative functions of genotype 2 E1E2 coevolution clusters. We aligned 30 E1E2
amino acid sequences of HCV genotype 2 (2a and 2b) and, using the BIS method, we identified
21 clusters (S6 Fig; S3, S7 Table). Genotype 2 clusters harboring blocks that mapped residues
previously reported in the literature to have a specific function are classified. The known role
(s) of the residues in each cluster are indicated: Folding or heterodimerization (blue), viral
binding site conformation (green) or fusion mechanism (red). According to these roles, clus-
ters are categorized into three different categories: structural (Folding, heterodimerization and
viral binding site conformation), fusion or multifunctional cluster. Clusters harboring blocks
that did not map any residues with a previously reported function were classified as clusters
with “undefined role”.
(DOCX)
S10 Table. BIS analysis of the coevolution of the transmembranes of E1 and E2. List of clus-
ters identified by BIS that connect the transmembrane of E1 and E2. Six clusters were identi-
fied across the two major HCV genotypes. Location of the transmembrane domains within E1
and E2 are indicated for each genotype and sub-types. Position of the coevolving blocks
located within the transmembrane of E1 and E2 are indicated for each cluster. TMD, Trans-
membrane Domain. Only significant clusters are reported (p value0.05).
(DOCX)
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S1 Fig. BIS methodology for coevolution analysis. Coevolution analyses require the identifi-
cation of sequence variability and they are usually realized on families of homologous protein
sequences, typically very divergent and represented by a large number of sequences. In con-
trast, studying viral sequences requires methods that can analyze serotypes and genotypes, usu-
ally constituted by a limited number of conserved sequences. BIS allows to track small parallel
changes likely corresponding to compensatory patterns preserving the structure and function
of the protein. Given a sequence alignment, the coevolution analysis method Blocks In
Sequences (BIS) [22–24] identifies groups of residues where mutations are present, at the same
time, in the same sequences. BIS allows to track small parallel changes likely corresponding to
compensatory patterns preserving the structure and function of the protein. BIS first detects
coevolution among each pair of alignment positions (left) and associates a coevolution score to
the pairs. At different colors match different coevolution scores (from red for high coevolution
score to blue for none). A coevolution score matrix between all alignment positions is con-
structed (top right) and clustered in such a way that groups of positions displaying the same
coevolution scores with all other positions in the alignment are identified (bottom right). The
schema illustrates two clusters made of four blocks (cluster A and B). Each cluster is composed
of blocks displaying a similar pattern of coevolution scores (here represented by a similar color
pattern). Cluster A is constituted by six positions organized in four blocks, three of them corre-
sponding to single residue positions and one of them made of three consecutive residue posi-
tions. Cluster B is made of four positions organized in four blocks, one of them corresponding
to single residue positions and three of them to two or three consecutive residue positions. For
both clusters, blocks belong to either E1 or E2 protein. An illustration of how these blocks can
be displayed on a linear sequence (E1) or on a protein structure (E2core) is shown. This figure
has been adapted from the figure 2 of the reference [23].
(TIF)
S2 Fig. Structural mapping of DENV E clusters. Mapping of the DENV E clusters 3 to 12
(illustrated by distinct colors) on the E dimeric structure (PDB 1K4R). For each cluster, posi-
tions of the coevolving blocks in E sequence are displayed within “strips” located above each
structure (See S2 Table for cluster positions). Each cluster is identified by a distinct color.
Cluster 1 and 2 were too large to be considered. A linear representation of Dengue E protein is
also shown at the top of the figure. Starting and ending residue positions of each E domain are
indicated. E domains are annotated by distinct colors: DI, domain I (red); DII, domain II (yel-
low); DIII, domain III (blue); Tmd, transmembrane (black).
(TIF)
S3 Fig. Coevolution analysis of HCV E1E2 genotype 1a sequences. The 16 gt1a clusters
(illustrated by distinct colors) are displayed within “strips” representing the E1E2 sequence.
For each cluster, positions of the coevolving blocks in the E1E2 sequence are indicated within
the corresponding “strip” (see S4 Table for cluster positions). On the top of each coevolving
block is indicated the corresponding protein or E2 domain the block belongs to: HVR1, Hyper
Variable Region 1; FL, Front Layer; VR2, Variable Region 2; βS, β-Sandwich; BinL, CD81
Binding Loop; BL, Back Layer; Stem; Tmd, Transmembrane domain). Two small linear repre-
sentations of HCV E1E2 are located at the top of each “strip” column, and can be used as refer-
ence for determining the position of each coevolving block within the E1E1 sequence. At the
top of the figure is shown an enlarged linear representation of HCV E1E2, where the starting
and ending residue positions of each protein and domain are indicated. E2 domains are
highlighted by distinct colors (Green, BL; Red, central β-sandwich; Blue, front layer; Dark
blue, CD81 BinL/CD81 binding loop; Light grey, central β-sandwich–back layer linker; Black
dotted line, VR2/Variable Region 2; Grey dotted line, Stem; Black rectangle, Tmd/
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Transmembrane).
(TIF)
S4 Fig. Mapping of genotype 1a cluster blocks on E1E2 reference sequences of genotype 1a
(H77; AF009606) and genotype 2a (JFH-1; AB047639). Genotype 1a cluster blocks are repre-
sented as red horizontal bars positioned above the E1 and E2 H77 or JFH-1 aligned sequences.
Each horizontal bar is numerated as follow: “Cluster ID-Block N˚”. Respective positions of
these blocks are referenced in S5 Table. Residues (boxes) or domains (horizontal arrows) pre-
viously identified in the literature to have a function are indicated (see Materials and Methods
for references). A color code, reported below the sequence alignment, links residues (boxes) or
domains (arrow) to specific functions according to the literature: blue for folding/heterodi-
merization, green for binding and red for fusion. Multi-colored code boxes represent residues
with two identified functions. In E2, the AR3A antibody epitope is shown as three orange
arrows. The putative function determined for each cluster is summarized in S6 Table. The
addition of one amino acid on the left and on the right of each block is considered to take into
account potential structural adjustments after mutation that are not considered in BIS calcula-
tion. Cluster blocks positions are numbered according to H77 gt1a (AF009606; S4 Table).
(TIF)
S5 Fig. Structural analysis of genotype 1a HCV E1E2 clusters. HCV E1E2 gt1a multifunc-
tional clusters 4 (blue) and 16 (orange) (A), structural clusters 11 (orange), 2 (green) and 6
(red) (B) and undefined role clusters 3 (pink), 9 (emerald green), 13 (brown), 14 (blue) and 15
(yellow) (C) are plotted on a vertical linear representation of E1 and on a tridimensional view
of E2 core (PDB 4MWF). Each cluster is composed of blocks harboring a similar color, accord-
ing to S3 Fig. The Stem region (Stem) is represented by a dotted line after the C-terminal part
of the BL. The transmembrane domain (Tmd) is represented as a rectangle following the Stem
region. In B and C, bold lines link E1 and E2 blocks that coevolve. For each cluster, block posi-
tions in E1 (at the left of the linear structure) and E2 (below boxes whose color match the color
of the corresponding cluster) are indicated. In A, the E2 central scaffold is enlarged and red
circles highlight regions where cluster 4 blocks are in close proximity. Rotation angles of the
E2core structure are indicated. Viewing angle of E2core is indicated by a black cross (Refer-
ence: Fig 3B). FL, Front Layer; BinL, CD81 Binding Loop; VR2, Variable Region 2; BL, Back
Layer; βS, β-Sandwich.
(TIF)
S6 Fig. Genotype 2 HCV E1E2 coevolution networks. The 21 gt2 clusters (illustrated by dis-
tinct colors) are displayed within “strips” representing the E1E2 sequence. For each cluster,
positions of the coevolving blocks in the E1E2 sequence are indicated within the correspond-
ing “strip” (see S7 Table for cluster positions). On the top of each coevolving block is indicated
the corresponding protein or E2 domain the block belongs to: HVR1, Hyper Variable Region
1; FL, Front Layer; VR2, Variable Region 2; βS, β-Sandwich; BinL, CD81 Binding Loop; BL,
Back Layer; Stem; Tmd, Transmembrane domain). Two small linear representations of HCV
E1E2 are located at the top of each “strip” column, and can be used as reference for determin-
ing the position of each coevolving block within the E1E1 sequence. At the top of the figure is
shown an enlarged linear representation of HCV E1E2, where the starting and ending residue
positions of each protein and domain are indicated. E2 domains are highlighted by distinct
colors (Green, BL; Red, central β-sandwich; Blue, front layer; Dark blue, CD81 BinL/CD81
binding loop; Light grey, central β-sandwich–back layer linker; Black dotted line, VR2/Vari-
able Region 2; Grey dotted line, Stem; Black rectangle, Tmd/Transmembrane).
(TIF)
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S7 Fig. Mapping of genotype 2 cluster blocks on E1E2 reference sequences of genotype 1a
(H77; AF009606) and genotype 2a (JFH-1; AB047639). Genotype 2 cluster blocks are repre-
sented as blue horizontal bars positioned above the E1 and E2 H77 or JFH-1 aligned
sequences. Each horizontal bar is numerated as follow: “Cluster number-Block N˚”. Respective
positions of these blocks are referenced in S8 Table. Residues (boxes) or domains (horizontal
arrows) previously identified in the literature to have a function are indicated (see Online
Methods for references). A color code, reported below the sequence alignment, links residues
(boxes) or domains (arrow) to specific functions according to the literature: blue for folding/
heterodimerization, green for binding and red for fusion. Multi-colored code boxes represent
residues with two identified functions. In E2, the AR3A antibody epitope is shown as three
orange arrows. The putative function determined for each cluster is summarized in S9 Table.
The addition of one amino acid on the left and on the right of each block is considered to take
into account potential structural adjustments after mutation that are not considered in BIS cal-
culation. Cluster blocks positions are numbered according to JFH-1 gt2 (AB047639; S7
Table).
(TIF)
S8 Fig. Structural analysis of the genotype 2 HCV E1E2 clusters. (A) Plot of the gt2 struc-
tural cluster 19 on a tridimensional view of the E2core structure (PDB 4MWF). Gt2 structural
(B), multifunctional (C), structural and multifunction (D), fusion (E) and undefined (F) clus-
ters were plotted both on a vertical linear representation of E1 and onto the E2 core structure.
Each cluster is composed of blocks harboring a similar color, according to S6 Fig. The Stem
region (Stem) is represented by a dotted line after the C-terminal part of the BL. The trans-
membrane domain (Tmd) is represented as a rectangle following the Stem region. In (B) and
(C,E,F), bold lines link E1 and E2 blocks that coevolved. For each cluster, block positions in E1
(at the left of the linear structure) and E2 (below boxes whose color match the color of the cor-
responding cluster) are indicated. Inter-E1E2 interactions mediated by gt2 structural clusters
7, 8, 11 and intra-E2 interactions mediated by gt2 structural cluster 18 and 21 are represented
in B, while multifunctional clusters 5 and 12 are represented in (C). Areas of close proximity
between blocks in cluster 19 (A) and between blocks in cluster 11 (D) and 12 (D) are enlarged
and highlighted by red circles. Panel E shows gt2 fusion clusters 6, 16 and 17. Panel F shows
gt2 undefined role clusters 3, 4, 9, 14, 15 and 20. Rotation angles of the E2core structure are
indicated. Viewing angle of E2core is indicated by a black cross (Reference: Fig 3B). HVR1,
Hyper Variable Region 1, FL, Front Layer; BinL, CD81 Binding Loop; BL, Back Layer, βS, β-
sandwich.
(TIF)
S9 Fig. Structural analysis of genotype 3 clusters involving E1 and the BL. Genotype 3 clus-
ter 4 (blue), cluster 8 (red) and cluster 9 (green) are plotted on a tridimensional view of the
E2core structure (PDB 4MWF) and on a vertical linear representation of E1. Each cluster is
composed of blocks harboring a similar color. The Stem region (Stem) is represented by a dot-
ted line after the C-terminal part of the BL. The transmembrane domain (Tmd) is represented
as a rectangle following the Stem region. The BL region is highlighted with a dotted circle on
the E2core structure and enlarged alone at the right of the E1 linear representation. Bold lines
link E1 and E2 blocks that coevolved. For each cluster, block positions in E1 (at the left of the
linear structure) and E2 (below boxes whose color match the color of the corresponding clus-
ter) are indicated. Rotation angles of the E2core structure are indicated. Viewing angle of
E2core is indicated by a black cross (Reference: Fig 3B). Genotype 3 cluster positions are avail-
able through the following webpage: http://www.lcqb.upmc.fr/HCVenv/HCVenv.html/.
(TIF)
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S10 Fig. Biophysical properties and ELISA detection of soluble BLd-H77. (A) Amino acid
sequence of the soluble BLd-H77. Dotted lines represent internal disulfide bridges that might
be involved in the functional folding of the soluble BLd-H77. (B) Detection of BLd-H77 in
reducing and non-reducing condition following SDS-Page electrophoresis and coomassie blue
staining. (C) Size distribution profiles as a function of the intensity and volume of soluble
BLd-H77, by Dynamic Light Scattering. The graph shows the superposition of three successive
measurements from 12 runs at each concentration, which are representative for at least three
independent experiments. (D) Far UV circular dichroism spectrum of soluble BLd-H77 after
purification by size exclusion chromatography.
(TIF)
S11 Fig. BLd-H77 inhibits HCV infection. (A) Quantification of HCVcc infectious titers fol-
lowing dose-dependent neutralization of HCVcc H77/JFH-1 by BLd-H77. Four days following
BLd-H77 dose-dependent neutralization of HCVcc H77/JFH-1 infection (see Fig 4F), Huh7.5
cell culture supernatants were harvested and used to infect naïve Huh7.5 cells. Four days post-
secondary infection, viral titers were determined by NS5A immunostaining (mean ± SD;
n = 3). (B) Average IC50 of BLd-H77 inhibition (μg/ml) for HCVpp or HCVcc particles of dif-
ferent genotypes or sub-types. ND, not determined. (C) Bafilomycin A1 and AR4A mediated-
inhibition of HCV entry. Huh7.5 cells (cells) or HCVpp (HCVpp-H77, virus) were incubated
1h with Bafilomycin A1 (20nM) or AR4A (25μg/ml) prior infection (2), during the 4h infec-
tion (3) or following infection (4). As control, cells were incubated at each step with equivalent
volume of PBS (1). Percentages of infection were calculated 72 post infection based on viral
titer obtained from control conditions. (mean ± SD; n = 3). Statistical significances (p<0.05,
p<0.001, ns non-significant) were determined for each experimental condition versus con-
trol condition (100%). N.A., non applicable, as significant cell death was observed for this
experimental condition. (D) HCV receptors expression is not impaired by BLd-H77. CD81,
SR-BI, Claudin-1 and Occludin expression in Huh7.5 cells pre-incubated overnight with PBS
(upper line) or BLd-H77 (50μg/ml; bottom line). Following PBS or BLd-H77 pre-incubation,
cells were fixed, permeabilized (only for Occludin staining) and stained for the different HCV
receptors with (white areas) or without (grey areas) receptor-specific antibody. Expression lev-
els were then determined by flow cytometry. Data are representative of two independent
experiments. (E) BLd-H77 inhibition of cell-to-cell transmission. After HCVcc H77/JFH-1
infection, cells were pre-incubated with PBS (control), with AP33 antibody alone (25μg/ml) or
with AP33 mixed with BLd-H77 (35μg/ml). Average numbers of cells per foci were determined
by immunostaining for each condition 4 days post infection. p<0.01, ns non-significant. (F)
Titration of primary human hepatocytes (PHH) cell culture media following HCVcc JC1 virus
infection. PHH were infected with HCVcc JC1 virus at different m.o.i. 4 days post-infection,
PHH cell culture supernatants were used to infect Huh7.5 cells. Viral titers were determined 4
days post-secondary infection via NS5A immunostaining (mean ± SD; n = 3). (G) BLd-H77
mediated-inhibition of patient-derived HCV particles in vivo. Patient-derived HCV particles
were pre-incubated with PBS or BLd-H77 (30μg/ml) and were used to infect primary human
hepatocytes (m.o.i. 0.1). Four days post-infection, cell culture supernatants were harvested and
viral load from primary infection were determined using a clinical diagnostic kit. Limit of
detection (l.o.d.) of the kit is indicated by a dotted line (n = 1 due to the limited amount of
patient sera available). (H) Serum-derived HCV viral loads from a mouse cohort treated with
150μg of BLd-H77 (blue square, n = 5) or with PBS (red circle, n = 7) under a “prophylactic”
protocol. BLd-H77 or PBS was injected one day prior virus infection with patient serum as
conducted in Fig 4L. Serum-derived HCV particle viral loads were determined as described in
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online methods. The limit of detection (l.o.d.) is indicated within the graph (dotted line). Viral
loads below the dotted line represent non-quantifiable viral loads. One non-engrafted liver
mice and one non-infected mice were used as negative controls (green, n = 2). A statistical
analysis was realized on all quantifiable viral loads for all time points (p = 0.02). (I) Serum
albumin concentration in humanized liver FRG mice prior infection and (Pre-infection) at the
time of sacrifice (Week 3). Albumin concentration were determined in the context of HCVcc
JC1 (JC1) and serum-derived HCV infection (Serum), and with BLd-H77 treatment (BLd) or
not (PBS). Medians are shown for each experimental group. (5–7 mice per group). ns non-sig-
nificant.
(TIF)
S12 Fig. BLd-H77 transmembranous form inhibits HCV infection. (A) Cell surface staining
of C46 and BLd-tm following transduction of Huh7.5. Expression of C46 and BLd-tm (white)
was measured by flow cytometry using an anti-hinge human IgG2 antibody and compared to
the level of expression within non-transduced Huh7.5 (Grey). (B) CD81, SR-BI, Claudin-1
and Occludin expression within Huh7.5 (left column) and Huh7.5 expressing the transmem-
branous form of the BLd-H77 (Huh7.5-BLd-tm) (right column) cells. Cells were fixed, per-
meabilized (only for Occludin staining) and stained for the different HCV receptors with
(white areas) or without (grey areas) receptor-specific antibody. Expression levels were then
determined by flow cytometry. Data are representative of two independent experiments. (C)
Effect of BLd-tm expression on cell-to-cell viral spread. Huh7.5, Huh7.5-C46, Huh7.5-BLd-tm
cells were infected by H77/JFH-1 HCVcc. Four days post-infection, average number of cells
per foci were determined for each cell type (mean ± SD; n = 3). p<0.001, ns non-significant.
(D) Retention of HCVpp particles at the Huh7.5-BLd-tm cell surface. Huh7.5 (left) and
Huh7.5-BLd-tm (right) were infected with H77 HCVpp particles. Presence of HCV E2 at the
cell surface was quantified by flow cytometry using anti-E2 H53 antibody. Gating were set up
on non-infected Huh7.5 (left) and Huh7.5-BLd-tm (right). Data are representative of two
independent experiments. (E) Interaction between BLd-H77 and sE2 detected by ELISA. Dif-
ferent amounts of mouse IgG isotype, AR3B and BLd-H77 were coated overnight into 96-well
plates. Coated peptides and antibodies were then incubated with 10ng of soluble E2 (sE2).
After washing, soluble E2 was detected using the anti-E2 antibody 3/11 or a rat isotype IgG
antibody. Following incubation with an anti-rat HRP antibody, 3/11 binding specificity to E2
was determined by calculating the ratio of O.D. between condition using 3/11 antibody and
the rat isotype IgG antibody, for each coating condition (mean ± SD; n = 3). p<0.0001, ns
non-significant.
(TIF)
S13 Fig. Effect of BLd-H77 on E2 and HCV pseudoparticles binding. (A) BLd-H77 effect on
E2 and HCVpp binding to Huh7.5 cells (Left). Huh7.5 cells, pre-incubated with PBS (top pan-
els) or BLd-H77 (50μg/ml) (bottom panels), were mixed (white) or not (grey), at 37˚C for 1h
with soluble E2 or with concentrated H77-HCVpp. Bound soluble E2 or HCVpp were then
stained with an anti-6his tag antibody or an anti-E2 antibody, respectively. Binding was then
quantified by flow cytometry following incubation with appropriate APC antibody. Data are
representative of two independent experiments. Ability of BLd-H77 to bind to Huh7.5 cell
membrane (Right). BLd-H77 (50μg/ml, white) or PBS (grey) was incubated for 1h at 37˚C
with Huh7.5 cells. Absence of bound BLd-H77 at Huh7.5 cell surface was verified by flow
cytometry following staining using an anti-6his antibody or an anti-E2 antibody as control.
(B) Expression of CD81 and SR-BI at BRL cell surface and HCVpp binding. BRL cell lines
were transduced by vectors encoding human CD81 or SR-BI (hSR-BI). After selection, naïve
BRL (grey) or transduced-BRL (white) cells were stained by anti-CD81 or anti-hSR-BI and by
A coevolution approach to decrypt the HCV fusion mechanism
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1006908 March 5, 2018 34 / 40
the appropriate secondary APC antibody. Quantification of CD81 and hSR-BI expression was
determined by flow cytometry. (C) BLd-H77 effect on E2 and HCVpp binding to CD81 and
hSR-BI. Naïve BRL (grey) or HCV-receptor expressing BRL (white) cells were mixed with con-
centrated H77-HCVpp pre-incubated with PBS (top panels) or BLd-H77 (50μg/ml) (bottom
panels). Bound HCVpp were then stained with an anti-E2 antibody and with an appropriate
APC antibody. Binding was then quantified by flow cytometry following incubation. Data are
representative of three independent experiments. (D) Relative quantification of HCVpp bind-
ing to BRL cells expressing exogenous hCD81 or hSR-BI. Binding of HCVpp is presented as
percentage of binding, relatively to the binding efficiency of HCVpp pre-incubated with PBS.
(mean ± SD; n = 3). Statistical significances (p<0.05, ns non-significant) were determined for
each experimental condition versus control condition (100%). (E) Competitive entry inhibi-
tion assay using BLd-H77 and a neutralizing anti-E1E2 antibody. HCVpp-H77 were incubated
for 1h at room temperature with BLd-tm (35 or 50 μg/ml), AR4A antibody (2 or 17 μg/ml) or
with both protein (35 and 2 μg/ml or 35 and 17 μg/ml), and used to infect Huh7.5. Percentage
of infection were quantified 72h post infection and calculated according to viral titer obtained
for control conditions (mean ± SD; n = 3). p<0.05, p<0.01.
(TIF)
S14 Fig. Effect of BLd-H77 on cell-cell fusion. (A) LTRhiv-luciferase vector transduced 293T
cells expressing H77 HCV (left panel) or VSV (right panel) envelope glycoproteins were co-
cultured with Tat-expressing Huh7.5 cells. Co-culture were pre-incubated for 1h with 50μg/ml
of BLd-H77 or PBS, washed and incubated for 3 min with a pH7 (red) or pH5 (orange) buffer.
Luciferase activities were determined 72h post-exposure. Results are presented in relative light
units (RLU) for each experimental condition (mean ± SD; n = 3). p<0.05, p<0.01. Statisti-
cal significances represent the significant differences between pH5 and pH7 condition, for
each viral envelope and treatment (PBS or BLd-H77). (B) Inhibitory effect of the BLd-H77
prior and following pH shock. Co-cultures were either pre-incubated with BLd-H77 (50μg/ml,
2) for 1h prior pH shock (pH5), for 24h following pH shock (50μg/ml, 3) or both (4). As a
control, co-cultures were pre-incubated with PBS for 1h prior pH shock, followed by an addi-
tional 24h incubation (1). 24h later, cells were washed and incubated for 48h. Relative fusion
efficiency at pH5 between control (pre- and post-treated by PBS) and the different BLd-H77
incubation periods are indicated (mean ± SD; n = 3). Statistical significances (p<0.05, p<
0.001, ns non-significant) were determined for each experimental condition versus control
condition (100%). (C) Specificity of HCVpp-liposome fusion assay. No enveloped HCVpp,
H77 HCVpp, fusion mutant E1E2 HCVpp particles and HANApp particles (Retroviral parti-
cles pseudotyped with Influenza Hemagglutinin-Neuraminidase) were mixed with R18-
labelled liposomes. Dequenching of R18 was quantified following sample acidification (pH5)
over 5 minutes (300 seconds). Data are represented as non-linear polynomial fitted curves and
display the evolution of the fusion rate from the time of acidification, relatively to the HCVpp-
H77 fusion rate which has been normalized at 100% at 300s post acidification. Curves are rep-
resentative of three independent experiments.
(TIF)
S15 Fig. Functional linkage of E1 and BL coevolving residues identified by BIS. (A) Protein
sequence alignment of E1E2 J6 and 2b1. Level of conservation for each amino acid position is
indicated. Position of the coevolving blocks that belong to gt2 fusion cluster 5 are indicated by
red rectangles. Position of the interchanged amino acid regions between J6 and 2b1 for the
construction of the J6/2b1 chimeric envelope are shown (Region 1, 2 and 3). (B) Structural
location of the E2 gt2 cluster 5 block (orange) and of the five J6/2b1 amino acids differences
(blue, 1 to 5) within the E2 BL. A dotted line symbolizes the rational experimental dissection
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of the BL into two distinct sub-domains, noted region 2 (non-β sheet region) and region 3 (β
sheet region), based on the distinct rearrangement of these two sub-domains. The distinct
structural contexts of the mutation 1–2 (region 2, left) and of the mutation 3–5 (region 3,
right) are highlighted. (C) J6/2b1 E2 chimera expression and incorporation onto HCVpp.
Expression in transfected 293T cells (Cell lysates) and incorporation onto concentrated pseu-
doparticles (Viral Pellets) of E2 from J6, 2b1 and J6/2b1 chimera. Detection of E2 on pseudo-
particles harboring no envelope glycoproteins was used as negative control. MLV-Capsid (CA)
was detected to control equivalent HCVpp production between chimera. (D) Quantification
of HCV viral RNA in the supernatant of Huh7.5 cell electroporated with viral RNA coding for
HCVcc harboring different J6/2b1 envelope chimera. Cell culture supernatant were harvested
at 48h and 72h post electroporation and viral RNA copy numbers per ml were determined by
RT-qPCR for each viral strain (mean ± SD; n = 4). p<0.05, p<0.01.
(TIF)
S16 Fig. Construction of E1-E2 genotype 1a chimera to challenge BIS predictions. Protein
sequence alignment of E1E2 H77 and A40. Level of conservation for each amino acid position
is indicated. Position of the E1 and E2 block of interest belonging to the gt1a cluster 5 are indi-
cated by red asterisks. Position of the three H77 amino acid residues that will be replaced by
A40 residues for the construction of H77/A40 chimeric envelopes are indicated by red rectan-
gles (two in E1 and one in E2).
(TIF)
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